PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
17265571-0	2006	Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective Inhibitor etoricoxib.	Etoricoxib	104-114	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	78-83
17265571-1	2006	BACKGROUND: A pooled analysis of randomized clinical trials data was performed to compare the rate of thrombotic cardiovascular events (thrombotic events) in patients taking the COX-2 selective inhibitor (coxib) etoricoxib, a traditional NSAID, or placebo.	Etoricoxib	212-222	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	178-183
16875903-3	2006	The MEDAL program is designed to provide a precise estimate of the relative cardiovascular event rates with the COX-2 selective inhibitor etoricoxib in comparison to the traditional NSAID diclofenac in patients with osteoarthritis and rheumatoid arthritis.	Etoricoxib	138-148	prostaglandin-endoperoxide synthase 2	Homo sapiens	112-117
16397127-5	2006	Selective inhibition of cyclooxygenase 2-dependent prostacyclin (by rofecoxib or etoricoxib) was associated with increased urinary excretion of 11-dehydro-TXB(2) in carriers of TLR4 polymorphisms, but not in wild-type, suggesting a restrainable effect of prostacyclin on platelet function in vivo in this setting.	Etoricoxib	81-91	prostaglandin-endoperoxide synthase 2	Homo sapiens	24-40
16616494-1	2006	The preparation of the sulfoxide analogues 2 and 4, and their enantiomeric pure forms is discussed as well as their potential to act as prodrugs to the potent and selective sulfone-containing COX-2 inhibitors rofecoxib and etoricoxib.	Etoricoxib	223-233	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	192-197
16892790-0	2006	Safety of etoricoxib, a specific cyclooxygenase-2 inhibitor, in asthmatic patients with aspirin-exacerbated respiratory disease.	Etoricoxib	10-20	prostaglandin-endoperoxide synthase 2	Homo sapiens	33-49
16892790-3	2006	OBJECTIVES: To study the safety of etoricoxib, a specific cyclooxygenase-2 inhibitor, and to determine whether it cross-reacts with asthma in patients with aspirin-exacerbated respiratory disease (AERD).	Etoricoxib	35-45	prostaglandin-endoperoxide synthase 2	Homo sapiens	58-74
16397127-5	2006	Selective inhibition of cyclooxygenase 2-dependent prostacyclin (by rofecoxib or etoricoxib) was associated with increased urinary excretion of 11-dehydro-TXB(2) in carriers of TLR4 polymorphisms, but not in wild-type, suggesting a restrainable effect of prostacyclin on platelet function in vivo in this setting.	Etoricoxib	81-91	toll like receptor 4	Homo sapiens	177-181
16291600-1	2006	This 2-part, double-blind, placebo-controlled study was conducted to determine the safety and efficacy of etoricoxib, a COX-2 selective inhibitor, for the treatment of hemophilic arthropathy.	Etoricoxib	106-116	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	120-125
16598848-0	2006	Different COX-independent effects of the COX-2 inhibitors etoricoxib and lumiracoxib.	Etoricoxib	58-68	cytochrome c oxidase subunit 8A	Homo sapiens	10-13
16598848-0	2006	Different COX-independent effects of the COX-2 inhibitors etoricoxib and lumiracoxib.	Etoricoxib	58-68	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	41-46
16598848-1	2006	Etoricoxib and lumiracoxib are both highly selective COX-2 inhibitors.	Etoricoxib	0-10	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	53-58
16598848-6	2006	On the other hand, activation of the transcription factor CREB was dose-dependently inhibited only by etoricoxib.	Etoricoxib	102-112	cAMP responsive element binding protein 1	Homo sapiens	58-62
16598848-9	2006	In conclusion, we showed that etoricoxib and lumiracoxib have different COX-independent mechanisms which may be of clinical relevance.	Etoricoxib	30-40	cytochrome c oxidase subunit 8A	Homo sapiens	72-75
16454836-0	2006	The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases.	Etoricoxib	62-72	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	86-91
16454836-2	2006	Etoricoxib is a new antiinflammatory inhibitor that has high Cox-2 selectivity.	Etoricoxib	0-10	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	61-66
16224508-1	2005	OBJECTIVE: To determine the risk of thromboembolic cardiovascular events associated with the use of etoricoxib, a COX-2 inhibitor.	Etoricoxib	100-110	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	114-119
16182319-2	2006	The present study was aimed to assess any possible interaction (additive or potentiation) in the antinociceptive effects of etoricoxib; a novel cyclooxygenase-2 inhibitor, and tramadol; a typical opioid agonist when administered in combination against mechanical hyperalgesia induced by spinal cord injury in rats.	Etoricoxib	124-134	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	144-160
17152346-0	2006	Interaction of non-steroidal anti-inflammatory drugs, etoricoxib and parecoxib sodium, with human serum albumin studied by fluorescence spectroscopy.	Etoricoxib	54-64	albumin	Homo sapiens	98-111
17152346-1	2006	The mechanism of interaction of the non-steroidal anti-inflammatory drugs, etoricoxib and parecoxib sodium, with human serum albumin (HSA) was studied using fluorescence spectroscopy.	Etoricoxib	75-85	albumin	Homo sapiens	119-132
16321158-1	2005	BACKGROUND: The aim of this study was to evaluate the long-term efficacy and tolerability of etoricoxib, a COX-2 selective inhibitor, in osteoarthritis (OA) patients.	Etoricoxib	93-103	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	107-112
16368055-7	2005	RESULTS: The least-squares mean time-weighted change from baseline LBP-IS score over 4 weeks was -32.94 mm (95% CI -36.25, -29.63) for etoricoxib, indicating substantial efficacy in relief of pain.	Etoricoxib	135-145	lipopolysaccharide binding protein	Homo sapiens	67-70
16224508-11	2005	However, the limited data that were available provide weak evidence of an increased cardiovascular risk with etoricoxib consistent with a class effect for COX-2 inhibitors.	Etoricoxib	109-119	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	155-160
16136765-0	2005	Safety of etoricoxib, a new cyclooxygenase 2 inhibitor, in patients with nonsteroidal anti-inflammatory drug-induced urticaria and angioedema.	Etoricoxib	10-20	prostaglandin-endoperoxide synthase 2	Homo sapiens	28-44
16192529-1	2005	UNLABELLED: In this randomized, double-blind, placebo-controlled, multicenter study we assessed the analgesic effect of etoricoxib (a new cyclooxygenase-2 inhibitor) in patients having had knee or hip replacement surgery.	Etoricoxib	120-130	prostaglandin-endoperoxide synthase 2	Homo sapiens	138-154
16054359-2	2005	The potential of this methodology has been demonstrated by the successful radiosynthesis of carbon-11 analogues of several highly selective cyclooxygenase-2 (COX-2) inhibitors such as Rofecoxib, Etoricoxib, and 3-(4-methylsulfonylphenyl)-4-phenyl-5-trifluoromethyl isoxazole in high yield.	Etoricoxib	195-205	prostaglandin-endoperoxide synthase 2	Homo sapiens	140-156
16054359-2	2005	The potential of this methodology has been demonstrated by the successful radiosynthesis of carbon-11 analogues of several highly selective cyclooxygenase-2 (COX-2) inhibitors such as Rofecoxib, Etoricoxib, and 3-(4-methylsulfonylphenyl)-4-phenyl-5-trifluoromethyl isoxazole in high yield.	Etoricoxib	195-205	prostaglandin-endoperoxide synthase 2	Homo sapiens	158-163
16136765-3	2005	OBJECTIVE: To investigate the clinical tolerance of NSAID-sensitive individuals to the selective COX-2 inhibitors etoricoxib and celecoxib.	Etoricoxib	114-124	prostaglandin-endoperoxide synthase 2	Homo sapiens	97-102
15990304-4	2005	Additionally, FlexX and CoMFA results also suggested that etoricoxib, another selective COX-2 inhibitor, could inhibit p38 MAP kinase.	Etoricoxib	58-68	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	88-93
15990304-4	2005	Additionally, FlexX and CoMFA results also suggested that etoricoxib, another selective COX-2 inhibitor, could inhibit p38 MAP kinase.	Etoricoxib	58-68	mitogen-activated protein kinase 14	Homo sapiens	119-133
16049609-1	2005	INTRODUCTION: Etoricoxib is a second generation cyclooxygenase-2 inhibitor with a rapid-onset time and a long duration of action.	Etoricoxib	14-24	prostaglandin-endoperoxide synthase 2	Homo sapiens	48-64
16083531-5	2005	Highly selective COX-2 inhibitors including celecoxib, rofecoxib, valdecoxib, lumiracoxib, and etoricoxib were developed with the hope of significantly reducing the serious gastrointestinal toxicities associated with chronic high-dose NSAID use.	Etoricoxib	95-105	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	17-22
16922642-1	2005	Etoricoxib is a highly selective COX-2 inhibitor (coxib) approved in Europe for the treatment of osteoarthritis (OA), rheumatoid arthritis and acute gouty arthritis.	Etoricoxib	0-10	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	33-38
16922642-7	2005	Similarly to other selective COX-2 inhibitors, etoricoxib is contraindicated in patients with ischaemic heart disease or stroke and it should be used with caution in patients with risk factors for heart disease.	Etoricoxib	47-57	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	29-34
15853965-0	2005	Protective effects of etoricoxib, a selective inhibitor of cyclooxygenase-2, in experimental periodontitis in rats.	Etoricoxib	22-32	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	59-75
15853965-1	2005	BACKGROUND: The purpose of the present study was to evaluate the effect of a potent selective cyclooxygenase-2 (COX-2) inhibitor, etoricoxib, on the prevention of alveolar bone loss in experimental periodontitis induced in rats.	Etoricoxib	130-140	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	94-110
15853965-1	2005	BACKGROUND: The purpose of the present study was to evaluate the effect of a potent selective cyclooxygenase-2 (COX-2) inhibitor, etoricoxib, on the prevention of alveolar bone loss in experimental periodontitis induced in rats.	Etoricoxib	130-140	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	112-117
15974563-2	2005	Etoricoxib, a COX-2 specific inhibitor, was developed to provide similar efficacy and less GI toxicity than non-selective NSAIDs.	Etoricoxib	0-10	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	14-19
15827069-0	2005	Etoricoxib: a highly selective COX-2 inhibitor.	Etoricoxib	0-10	prostaglandin-endoperoxide synthase 2	Homo sapiens	31-36
15827069-1	2005	OBJECTIVE: To review the available literature evaluating the pharmacology, pharmacokinetics, clinical efficacy, and adverse effects of etoricoxib, a highly selective cyclooxygenase-2 (COX-2) inhibitor that is not currently approved for use in the US.	Etoricoxib	135-145	prostaglandin-endoperoxide synthase 2	Homo sapiens	166-182
15827069-1	2005	OBJECTIVE: To review the available literature evaluating the pharmacology, pharmacokinetics, clinical efficacy, and adverse effects of etoricoxib, a highly selective cyclooxygenase-2 (COX-2) inhibitor that is not currently approved for use in the US.	Etoricoxib	135-145	prostaglandin-endoperoxide synthase 2	Homo sapiens	184-189
15815733-5	2005	RESULTS: Rofecoxib and the novel COX-2 inhibitors etoricoxib and valdecoxib have a higher degree of COX-2 selectivity than traditional NSAIDs.	Etoricoxib	50-60	prostaglandin-endoperoxide synthase 2	Homo sapiens	33-38
16372792-1	2005	The study is a prospective randomized double blind clinical trial comparing the efficacy of nonselective NSAIDs (Aceclofenac) and highly selective COX-2 inhibitors (Etoricoxib) in post extraction pain control.	Etoricoxib	165-175	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	147-152
15815733-5	2005	RESULTS: Rofecoxib and the novel COX-2 inhibitors etoricoxib and valdecoxib have a higher degree of COX-2 selectivity than traditional NSAIDs.	Etoricoxib	50-60	prostaglandin-endoperoxide synthase 2	Homo sapiens	100-105
15818702-1	2005	OBJECTIVE: To assess the efficacy, safety, and tolerability of etoricoxib, a cyclooxygenase 2 (COX-2) selective inhibitor, administered continuously over 52 weeks for the treatment of ankylosing spondylitis (AS).	Etoricoxib	63-73	prostaglandin-endoperoxide synthase 2	Homo sapiens	77-93
15818702-1	2005	OBJECTIVE: To assess the efficacy, safety, and tolerability of etoricoxib, a cyclooxygenase 2 (COX-2) selective inhibitor, administered continuously over 52 weeks for the treatment of ankylosing spondylitis (AS).	Etoricoxib	63-73	prostaglandin-endoperoxide synthase 2	Homo sapiens	95-100
15279595-1	2004	Valdecoxib, parecoxib, etoricoxib and lumiracoxib represent the second generation of selective COX-2 inhibitors.	Etoricoxib	23-33	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	95-100
15473012-1	2005	A practicable and selective liquid chromatography-mass spectrometry assay for the determination of two cyclooxygenase-2 inhibitors, etoricoxib and valdecoxib, in human plasma is presented.	Etoricoxib	132-142	prostaglandin-endoperoxide synthase 2	Homo sapiens	103-119
15664353-1	2005	A simple, sensitive and specific HPLC method with UV detection (284 nm) was developed and validated for quantitation of Etoricoxib in human plasma, the newest addition to the group of nonsteroidal anti-inflammatory drugs-a highly selective cyclooxygenase-2 inhibitor.	Etoricoxib	120-130	prostaglandin-endoperoxide synthase 2	Homo sapiens	240-256
15701208-0	2004	Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs.	Etoricoxib	115-125	prostaglandin-endoperoxide synthase 2	Homo sapiens	88-104
15701208-2	2004	OBJECTIVE: To compare the rates of new use of gastroprotective agents and discontinuations due to dyspepsia with the COX-2 selective inhibitor etoricoxib compared with non-selective NSAIDs.	Etoricoxib	143-153	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	117-122
15638077-1	2004	Etoricoxib is a potent and novel selective inhibitor of cyclooxygenase-2 (COX-2) which has been developed for the treatment of osteoarthritis, rheumatoid arthritis and several other inflammatory conditions.	Etoricoxib	0-10	prostaglandin-endoperoxide synthase 2	Homo sapiens	56-72
15638077-1	2004	Etoricoxib is a potent and novel selective inhibitor of cyclooxygenase-2 (COX-2) which has been developed for the treatment of osteoarthritis, rheumatoid arthritis and several other inflammatory conditions.	Etoricoxib	0-10	prostaglandin-endoperoxide synthase 2	Homo sapiens	74-79
15342613-0	2004	The effects of modifying in vivo cytochrome P450 3A (CYP3A) activity on etoricoxib pharmacokinetics and of etoricoxib administration on CYP3A activity.	Etoricoxib	72-82	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	33-51
15342613-0	2004	The effects of modifying in vivo cytochrome P450 3A (CYP3A) activity on etoricoxib pharmacokinetics and of etoricoxib administration on CYP3A activity.	Etoricoxib	72-82	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	53-58
15342613-1	2004	To investigate the influence of modifying in vivo cytochrome P450 3A (CYP3A) activity on the pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, and of etoricoxib administration on CYP3A activity, a 3-part, randomized, crossover study was conducted in 3 panels of healthy volunteers.	Etoricoxib	113-123	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	50-68
15342613-1	2004	To investigate the influence of modifying in vivo cytochrome P450 3A (CYP3A) activity on the pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, and of etoricoxib administration on CYP3A activity, a 3-part, randomized, crossover study was conducted in 3 panels of healthy volunteers.	Etoricoxib	113-123	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	70-75
15494548-5	2005	Valdecoxib potently inhibits recombinant COX-2, with an IC(50) of 0.005 microM; this compares with IC values of 0.05 microM for celecoxib, 0.5 microM for rofecoxib, and 5 microM for etoricoxib.	Etoricoxib	182-192	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	41-46
15494548-6	2005	Unique binding interactions of valdecoxib with COX-2 translate into a fast rate of inactivation of COX-2 (110,000 M/s compared with 7000 M/s for rofecoxib and 80 M/s for etoricoxib).	Etoricoxib	170-180	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	47-52
15494548-6	2005	Unique binding interactions of valdecoxib with COX-2 translate into a fast rate of inactivation of COX-2 (110,000 M/s compared with 7000 M/s for rofecoxib and 80 M/s for etoricoxib).	Etoricoxib	170-180	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	99-104
15494548-7	2005	The overall saturation binding affinity for COX-2 of valdecoxib is 2.6 nM (compared with 1.6 nM for celecoxib, 51 nM for rofecoxib, and 260 nM for etoricoxib), with a slow off-rate (t(1/2) approximately 98 min).	Etoricoxib	147-157	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	44-49
15117884-2	2004	Selective inhibitors of COX-2, such as celecoxib, etoricoxib, lumiracoxib, rofecoxib, and valdecoxib have been developed and the greatest recent growth in our knowledge in this area has been come from the clinical use of these compounds.	Etoricoxib	50-60	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	24-29
15100590-1	2004	OBJECTIVE: To compare the overall analgesic effect, including time to onset, peak and duration of effect for etoricoxib 120 mg, a new COX-2 selective inhibitor, in patients with acute pain to that of placebo.	Etoricoxib	109-119	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	134-139
15100590-8	2004	DISCUSSION: Etoricoxib is a new COX-2 selective inhibitor under development for treatment of osteoarthritis, rheumatoid arthritis, and acute pain.	Etoricoxib	12-22	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	32-37
15319795-1	2004	Etoricoxib (Arcoxia, Merck & Co., Inc.) is a selective inhibitor of cyclooxygenase-2 (COX-2), an enzyme involved in pain and inflammation.	Etoricoxib	0-10	prostaglandin-endoperoxide synthase 2	Homo sapiens	72-88
15319795-1	2004	Etoricoxib (Arcoxia, Merck & Co., Inc.) is a selective inhibitor of cyclooxygenase-2 (COX-2), an enzyme involved in pain and inflammation.	Etoricoxib	0-10	prostaglandin-endoperoxide synthase 2	Homo sapiens	90-95
15319795-1	2004	Etoricoxib (Arcoxia, Merck & Co., Inc.) is a selective inhibitor of cyclooxygenase-2 (COX-2), an enzyme involved in pain and inflammation.	Etoricoxib	12-19	prostaglandin-endoperoxide synthase 2	Homo sapiens	72-88
15319795-1	2004	Etoricoxib (Arcoxia, Merck & Co., Inc.) is a selective inhibitor of cyclooxygenase-2 (COX-2), an enzyme involved in pain and inflammation.	Etoricoxib	12-19	prostaglandin-endoperoxide synthase 2	Homo sapiens	90-95
15124935-5	2004	Selective COX-2 inhibitors currently used in the clinic are the sulphonamides celecoxib and valdecoxib (parecoxib is a prodrug of valdecoxib), as well as the methylsulphones rofecoxib and etoricoxib.	Etoricoxib	188-198	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	10-15
15270001-1	2004	Etoricoxib (Arcoxia) is a novel non steroidal anti-inflammatory drug (NSAID) that selectively inhibits the inducible form of cyclo-oxygenase (COX), COX-2.	Etoricoxib	0-10	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	148-153
15270001-2	2004	Etoricoxib has a higher COX-1/COX-2 selectivity ratio than the other COX-2-selective NSAIDs as rofecoxib, valdecoxib or celecoxib.	Etoricoxib	0-10	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	24-29
15270001-2	2004	Etoricoxib has a higher COX-1/COX-2 selectivity ratio than the other COX-2-selective NSAIDs as rofecoxib, valdecoxib or celecoxib.	Etoricoxib	0-10	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	30-35
14996519-1	2004	BACKGROUND: Based on the experience with selective cyclooxygenase (COX)-2 inhibitors, including rofecoxib, valdecoxib, and celecoxib, it was anticipated that etoricoxib, a new selective COX-2 inhibitor, would display mechanism-based, dose-dependent renal adverse effects (AEs) similar to those observed with nonselective non-steroidal anti-inflammatory drugs (NSAIDs) in long-term treatment.	Etoricoxib	158-168	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	51-73
14996519-1	2004	BACKGROUND: Based on the experience with selective cyclooxygenase (COX)-2 inhibitors, including rofecoxib, valdecoxib, and celecoxib, it was anticipated that etoricoxib, a new selective COX-2 inhibitor, would display mechanism-based, dose-dependent renal adverse effects (AEs) similar to those observed with nonselective non-steroidal anti-inflammatory drugs (NSAIDs) in long-term treatment.	Etoricoxib	158-168	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	186-191
15141994-7	2004	The specificity of etoricoxib for COX-2 has been found to be approximately 3-fold greater than that of rofecoxib and valdecoxib and approximately 14-fold more than celecoxib in human whole blood assays.	Etoricoxib	19-29	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	34-39
14965322-1	2004	Novel coxibs (i.e. etoricoxib, valdecoxib, parecoxib and lumiracoxib) with enhanced biochemical cyclooxygenase (COX)-2 selectivity over that of rofecoxib and celecoxib have been recently developed.	Etoricoxib	19-29	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	96-118
14965322-6	2004	Etoricoxib shows only a slightly improved COX-2 selectivity than rofecoxib, a highly selective COX-2 inhibitor that has been reported to halve the incidence of serious gastrointestinal toxicity compared to nonselective nonsteroidal antiinflammatory drugs (NSAIDs).	Etoricoxib	0-10	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	42-47
14965322-6	2004	Etoricoxib shows only a slightly improved COX-2 selectivity than rofecoxib, a highly selective COX-2 inhibitor that has been reported to halve the incidence of serious gastrointestinal toxicity compared to nonselective nonsteroidal antiinflammatory drugs (NSAIDs).	Etoricoxib	0-10	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	95-100
14681341-1	2004	The effect of renal insufficiency on the pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, was examined in 23 patients with varying degrees of renal impairment (12 moderate [creatinine clearance between 30 and 50 mL/min/1.73 m2], 5 severe [creatinine clearance below 30 mL/min/1.73 m2], and 6 with end-stage renal disease requiring hemodialysis) following administration of single 120-mg oral doses of etoricoxib.	Etoricoxib	61-71	prostaglandin-endoperoxide synthase 2	Homo sapiens	98-114
14552704-8	2003	Etoricoxib, showing only a slightly higher COX-2 selectivity than rofecoxib in vitro (COX-1/COX-2 ratio: 344 vs 272, respectively), has been reported to cause a similar specific COX-2 inhibition ex vivo that should translate into comparable GI safety.	Etoricoxib	0-10	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	43-48
15244490-2	2004	STUDY DESIGN: Decision-analytical modelling was used to calculate the expected costs and consequences of the use of etoricoxib compared with non-selective NSAIDs alone, NSAIDs plus proton pump inhibitors (PPIs), NSAIDs plus histamine H2 receptor antagonists and NSAIDs plus misoprostol over a continuous treatment period of 1 year.	Etoricoxib	116-126	histamine receptor H2	Homo sapiens	224-245
12705971-1	2003	The validation of a liquid chromatography-tandem mass spectrometry (LC-MS-MS) method for the determination of the selective cyclooxygenase-2 inhibitor etoricoxib in human plasma with phenazone as internal standard is described.	Etoricoxib	151-161	prostaglandin-endoperoxide synthase 2	Homo sapiens	124-140
12800464-2	2003	Etoricoxib, a selective COX2 inhibitor, has been shown to be as effective as non-selective non-steroidal anti-inflammatory drugs in the management of chronic pain in rheumatoid arthritis and osteoarthritis, for periods of up to one year.	Etoricoxib	0-10	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	24-28
12800464-7	2003	However, etoricoxib shows promise as a new and effective COX2 inhibitor in clinical practice.	Etoricoxib	9-19	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	57-61
14517196-1	2003	The effect of hepatic insufficiency on the pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, was investigated following administration of single and multiple oral doses to mild hepatic insufficiency patients (Child-Pugh score of 5 to 6), multiple oral doses to moderate hepatic insufficiency patients (Child-Pugh score of 7 to 9), and single intravenous doses to both mild and moderate hepatic insufficiency patients.	Etoricoxib	63-73	prostaglandin-endoperoxide synthase 2	Homo sapiens	100-116
12907325-0	2003	The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.	Etoricoxib	61-71	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	35-40
12817520-0	2003	Characterization of etoricoxib, a novel, selective COX-2 inhibitor.	Etoricoxib	20-30	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	51-56
12817520-1	2003	Etoricoxib is a potent selective COX-2 inhibitor in man.	Etoricoxib	0-10	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	33-38
12817520-12	2003	Based on these results, etoricoxib is a potent selective inhibitor of COX-2 after single and multiple dosing regimens and does not inhibit prostaglandin synthesis in the gastric mucosa, even at doses above the clinical dose range of 60 to 120 mg.	Etoricoxib	24-34	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	70-75
14552704-8	2003	Etoricoxib, showing only a slightly higher COX-2 selectivity than rofecoxib in vitro (COX-1/COX-2 ratio: 344 vs 272, respectively), has been reported to cause a similar specific COX-2 inhibition ex vivo that should translate into comparable GI safety.	Etoricoxib	0-10	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	86-91
14552704-8	2003	Etoricoxib, showing only a slightly higher COX-2 selectivity than rofecoxib in vitro (COX-1/COX-2 ratio: 344 vs 272, respectively), has been reported to cause a similar specific COX-2 inhibition ex vivo that should translate into comparable GI safety.	Etoricoxib	0-10	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	92-97
14552704-8	2003	Etoricoxib, showing only a slightly higher COX-2 selectivity than rofecoxib in vitro (COX-1/COX-2 ratio: 344 vs 272, respectively), has been reported to cause a similar specific COX-2 inhibition ex vivo that should translate into comparable GI safety.	Etoricoxib	0-10	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	92-97
12868201-3	2003	Slow, time-dependent, irreversible, highly selective inhibitors of COX-2 such as celecoxib, etoricoxib, rofecoxib and valdecoxib, so-called coxibs, are a new group of drugs widely used in rheumatology as well as in other fields of medicine.	Etoricoxib	92-102	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	67-72
12562317-0	2003	Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor.	Etoricoxib	25-35	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	55-59
12638395-0	2003	Single- and multiple-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, in man.	Etoricoxib	46-56	prostaglandin-endoperoxide synthase 2	Homo sapiens	83-99
12638395-1	2003	The single- and multiple-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, were examined in two clinical studies.	Etoricoxib	50-60	prostaglandin-endoperoxide synthase 2	Homo sapiens	87-103
12562317-1	2003	The development of COX2 inhibitors with improved biochemical selectivity (such as etoricoxib and valdecoxib) over that of commercially available coxibs has been driven by the potential advantage of safety using higher coxib doses for increased efficacy.	Etoricoxib	82-92	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	19-23
12562317-4	2003	Etoricoxib has an in vitro COX1/COX2 IC(50) ratio of 344, the highest of any coxib.	Etoricoxib	0-10	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	27-31
12562317-4	2003	Etoricoxib has an in vitro COX1/COX2 IC(50) ratio of 344, the highest of any coxib.	Etoricoxib	0-10	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	32-36
12562317-6	2003	The profound inhibition of monocyte COX2 activity at 24 h after dosing, as predicted by a pharmacological half-life of approximately 22 h, supports a once-daily dosing regimen of etoricoxib.	Etoricoxib	179-189	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	36-40
12534404-0	2003	Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib.	Etoricoxib	98-108	prostaglandin-endoperoxide synthase 2	Homo sapiens	60-77
12534404-2	2003	AIM: To assess the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib vs. non-selective non-steroidal anti-inflammatory drugs.	Etoricoxib	88-98	prostaglandin-endoperoxide synthase 2	Homo sapiens	50-67
12077033-1	2002	OBJECTIVE: To assess the safety and efficacy of etoricoxib, a selective cyclo-oxygenase-2 inhibitor, in comparison with indometacin in the treatment of acute gouty arthritis.	Etoricoxib	48-58	prostaglandin-endoperoxide synthase 2	Homo sapiens	72-89
12180720-1	2002	OBJECTIVE: To evaluate the efficacy and tolerability of the highly selective cyclooxygenase-2 (COX-2) inhibitor etoricoxib for the treatment of rheumatoid arthritis (RA).	Etoricoxib	112-122	prostaglandin-endoperoxide synthase 2	Homo sapiens	77-93
12180720-1	2002	OBJECTIVE: To evaluate the efficacy and tolerability of the highly selective cyclooxygenase-2 (COX-2) inhibitor etoricoxib for the treatment of rheumatoid arthritis (RA).	Etoricoxib	112-122	prostaglandin-endoperoxide synthase 2	Homo sapiens	95-100
11835200-0	2002	Simultaneous determination of unlabeled and carbon-13-labeled etoricoxib, a new cyclooxygenase-2 inhibitor, in human plasma using HPLC-MS/MS.	Etoricoxib	62-72	prostaglandin-endoperoxide synthase 2	Homo sapiens	80-96
12033987-1	2002	BACKGROUND: Etoricoxib is a highly selective COX-2 inhibitor which was evaluated for the treatment of rheumatoid arthritis (RA).	Etoricoxib	12-22	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	45-50
12564662-3	2002	Valdecoxib, etoricoxib, DFU and DFP inhibited platelet COX-1 and monocyte COX-2 with the following COX-1/COX-2 IC50 ratios: 61.5, 344, 660 and 1918, respectively.	Etoricoxib	12-22	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	105-110
12017209-1	2002	OBJECTIVE: To evaluate the efficacy of 12 weeks of treatment with etoricoxib, a selective COX-2 inhibitor, in patients with osteoarthritis (OA) of the knee or hip.	Etoricoxib	66-76	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	90-95
12564662-3	2002	Valdecoxib, etoricoxib, DFU and DFP inhibited platelet COX-1 and monocyte COX-2 with the following COX-1/COX-2 IC50 ratios: 61.5, 344, 660 and 1918, respectively.	Etoricoxib	12-22	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	55-60
12466002-1	2002	Etoricoxib is a cyclo-oxygenase (COX)-2-selective NSAID with a higher COX-1 to COX-2 selectivity ratio than the other COX-2-selective NSAIDs rofecoxib, valdecoxib or celecoxib.	Etoricoxib	0-10	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	70-75
12564662-3	2002	Valdecoxib, etoricoxib, DFU and DFP inhibited platelet COX-1 and monocyte COX-2 with the following COX-1/COX-2 IC50 ratios: 61.5, 344, 660 and 1918, respectively.	Etoricoxib	12-22	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	74-79
12564662-3	2002	Valdecoxib, etoricoxib, DFU and DFP inhibited platelet COX-1 and monocyte COX-2 with the following COX-1/COX-2 IC50 ratios: 61.5, 344, 660 and 1918, respectively.	Etoricoxib	12-22	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	99-104
12466002-1	2002	Etoricoxib is a cyclo-oxygenase (COX)-2-selective NSAID with a higher COX-1 to COX-2 selectivity ratio than the other COX-2-selective NSAIDs rofecoxib, valdecoxib or celecoxib.	Etoricoxib	0-10	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	79-84
11583479-0	2001	Dose proportionality of oral etoricoxib, a highly selective cyclooxygenase-2 inhibitor, in healthy volunteers.	Etoricoxib	29-39	prostaglandin-endoperoxide synthase 2	Homo sapiens	60-76
11717412-5	2001	The rank order of potencies for this process (ibuprofen > celecoxib > valdecoxib > rofecoxib > etoricoxib) parallels that obtained for the inhibition of Cox-1-mediated thromboxane B(2) production by calcium ionophore-stimulated platelets.	Etoricoxib	107-117	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	165-170
11160644-3	2001	Using the ratio of IC(50) values (COX-1/COX-2), the selectivity ratio for the inhibition of COX-2 by etoricoxib in the human whole blood assay was 106, compared with values of 35, 30, 7.6, 7.3, 2.4, and 2.0 for rofecoxib, valdecoxib, celecoxib, nimesulide, etodolac, and meloxicam, respectively.	Etoricoxib	101-111	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	34-39
11353749-0	2001	Role of human liver cytochrome P4503A in the metabolism of etoricoxib, a novel cyclooxygenase-2 selective inhibitor.	Etoricoxib	59-69	prostaglandin-endoperoxide synthase 2	Homo sapiens	79-95
11353749-1	2001	Etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, was shown to be metabolized via 6"-methylhydroxylation (M2 formation) when incubated with NADPH-fortified human liver microsomes.	Etoricoxib	0-10	prostaglandin-endoperoxide synthase 2	Homo sapiens	35-51
11353749-8	2001	Cytochrome P450 (P450) reaction phenotyping studies-using P450 form selective chemical inhibitors, immunoinhibitory antibodies, recombinant P450s, and correlation analysis with microsomes prepared from a bank of human livers-revealed that the 6"-methyl hydroxylation of etoricoxib was catalyzed largely (approximately 60%) by member(s) of the CYP3A subfamily.	Etoricoxib	270-280	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
11353749-10	2001	Moreover, etoricoxib (0.1-100 microM) was found to be a relatively weak inhibitor (IC(50) > 100 microM) of multiple P450s (CYP1A2, CYP2D6, CYP3A, CYP2E1, CYP2C9, and CYP2C19) in human liver microsomes.	Etoricoxib	10-20	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	126-132
11353749-10	2001	Moreover, etoricoxib (0.1-100 microM) was found to be a relatively weak inhibitor (IC(50) > 100 microM) of multiple P450s (CYP1A2, CYP2D6, CYP3A, CYP2E1, CYP2C9, and CYP2C19) in human liver microsomes.	Etoricoxib	10-20	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	134-140
11353749-10	2001	Moreover, etoricoxib (0.1-100 microM) was found to be a relatively weak inhibitor (IC(50) > 100 microM) of multiple P450s (CYP1A2, CYP2D6, CYP3A, CYP2E1, CYP2C9, and CYP2C19) in human liver microsomes.	Etoricoxib	10-20	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	142-147
11353749-10	2001	Moreover, etoricoxib (0.1-100 microM) was found to be a relatively weak inhibitor (IC(50) > 100 microM) of multiple P450s (CYP1A2, CYP2D6, CYP3A, CYP2E1, CYP2C9, and CYP2C19) in human liver microsomes.	Etoricoxib	10-20	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	149-155
11353749-10	2001	Moreover, etoricoxib (0.1-100 microM) was found to be a relatively weak inhibitor (IC(50) > 100 microM) of multiple P450s (CYP1A2, CYP2D6, CYP3A, CYP2E1, CYP2C9, and CYP2C19) in human liver microsomes.	Etoricoxib	10-20	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	157-163
11353749-10	2001	Moreover, etoricoxib (0.1-100 microM) was found to be a relatively weak inhibitor (IC(50) > 100 microM) of multiple P450s (CYP1A2, CYP2D6, CYP3A, CYP2E1, CYP2C9, and CYP2C19) in human liver microsomes.	Etoricoxib	10-20	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	169-176
11327589-0	2001	In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663).	Etoricoxib	133-143	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	117-122
11327589-0	2001	In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663).	Etoricoxib	145-152	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	117-122
11327589-1	2001	Characterization of the metabolites of the COX-2 inhibitor etoricoxib (MK-0663 and L-791,456) produced in vitro indicate formation of an N-oxide pyridine and hydroxymethyl pyridine that can further be glucuronidated or oxidized to an acid.	Etoricoxib	59-69	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	43-48
11327589-1	2001	Characterization of the metabolites of the COX-2 inhibitor etoricoxib (MK-0663 and L-791,456) produced in vitro indicate formation of an N-oxide pyridine and hydroxymethyl pyridine that can further be glucuronidated or oxidized to an acid.	Etoricoxib	71-78	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	43-48
11160644-0	2001	Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2.	Etoricoxib	0-10	prostaglandin-endoperoxide synthase 2	Homo sapiens	100-116
11160644-1	2001	We report here the preclinical profile of etoricoxib (MK-0663) [5-chloro-2-(6-methylpyridin-3-yl)-3-(4-methylsulfonylphenyl) pyridine], a novel orally active agent that selectively inhibits cyclooxygenase-2 (COX-2), that has been developed for high selectivity in vitro using whole blood assays and sensitive COX-1 enzyme assays at low substrate concentration.	Etoricoxib	42-52	prostaglandin-endoperoxide synthase 2	Homo sapiens	190-206
11160644-1	2001	We report here the preclinical profile of etoricoxib (MK-0663) [5-chloro-2-(6-methylpyridin-3-yl)-3-(4-methylsulfonylphenyl) pyridine], a novel orally active agent that selectively inhibits cyclooxygenase-2 (COX-2), that has been developed for high selectivity in vitro using whole blood assays and sensitive COX-1 enzyme assays at low substrate concentration.	Etoricoxib	42-52	prostaglandin-endoperoxide synthase 2	Homo sapiens	208-213
11160644-3	2001	Using the ratio of IC(50) values (COX-1/COX-2), the selectivity ratio for the inhibition of COX-2 by etoricoxib in the human whole blood assay was 106, compared with values of 35, 30, 7.6, 7.3, 2.4, and 2.0 for rofecoxib, valdecoxib, celecoxib, nimesulide, etodolac, and meloxicam, respectively.	Etoricoxib	101-111	prostaglandin-endoperoxide synthase 2	Homo sapiens	40-45
11160644-1	2001	We report here the preclinical profile of etoricoxib (MK-0663) [5-chloro-2-(6-methylpyridin-3-yl)-3-(4-methylsulfonylphenyl) pyridine], a novel orally active agent that selectively inhibits cyclooxygenase-2 (COX-2), that has been developed for high selectivity in vitro using whole blood assays and sensitive COX-1 enzyme assays at low substrate concentration.	Etoricoxib	42-52	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	309-314
11160644-1	2001	We report here the preclinical profile of etoricoxib (MK-0663) [5-chloro-2-(6-methylpyridin-3-yl)-3-(4-methylsulfonylphenyl) pyridine], a novel orally active agent that selectively inhibits cyclooxygenase-2 (COX-2), that has been developed for high selectivity in vitro using whole blood assays and sensitive COX-1 enzyme assays at low substrate concentration.	Etoricoxib	54-61	prostaglandin-endoperoxide synthase 2	Homo sapiens	190-206
11160644-3	2001	Using the ratio of IC(50) values (COX-1/COX-2), the selectivity ratio for the inhibition of COX-2 by etoricoxib in the human whole blood assay was 106, compared with values of 35, 30, 7.6, 7.3, 2.4, and 2.0 for rofecoxib, valdecoxib, celecoxib, nimesulide, etodolac, and meloxicam, respectively.	Etoricoxib	101-111	prostaglandin-endoperoxide synthase 2	Homo sapiens	92-97
11160644-1	2001	We report here the preclinical profile of etoricoxib (MK-0663) [5-chloro-2-(6-methylpyridin-3-yl)-3-(4-methylsulfonylphenyl) pyridine], a novel orally active agent that selectively inhibits cyclooxygenase-2 (COX-2), that has been developed for high selectivity in vitro using whole blood assays and sensitive COX-1 enzyme assays at low substrate concentration.	Etoricoxib	54-61	prostaglandin-endoperoxide synthase 2	Homo sapiens	208-213
11160644-1	2001	We report here the preclinical profile of etoricoxib (MK-0663) [5-chloro-2-(6-methylpyridin-3-yl)-3-(4-methylsulfonylphenyl) pyridine], a novel orally active agent that selectively inhibits cyclooxygenase-2 (COX-2), that has been developed for high selectivity in vitro using whole blood assays and sensitive COX-1 enzyme assays at low substrate concentration.	Etoricoxib	54-61	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	309-314
11160644-2	2001	Etoricoxib selectively inhibited COX-2 in human whole blood assays in vitro, with an IC(50) value of 1.1 +/- 0.1 microM for COX-2 (LPS-induced prostaglandin E2 synthesis), compared with an IC(50) value of 116 +/- 8 microM for COX-1 (serum thromboxane B2 generation after clotting of the blood).	Etoricoxib	0-10	prostaglandin-endoperoxide synthase 2	Homo sapiens	33-38
11160644-2	2001	Etoricoxib selectively inhibited COX-2 in human whole blood assays in vitro, with an IC(50) value of 1.1 +/- 0.1 microM for COX-2 (LPS-induced prostaglandin E2 synthesis), compared with an IC(50) value of 116 +/- 8 microM for COX-1 (serum thromboxane B2 generation after clotting of the blood).	Etoricoxib	0-10	prostaglandin-endoperoxide synthase 2	Homo sapiens	124-129
11160644-5	2001	In a highly sensitive assay for COX-1 with U937 microsomes where the arachidonic acid concentration was lowered to 0.1 microM, IC(50) values of 12, 2, 0.25, and 0.05 microM were obtained for etoricoxib, rofecoxib, valdecoxib, and celecoxib, respectively.	Etoricoxib	191-201	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	32-37
11160644-8	2001	In squirrel monkeys, etoricoxib reversed LPS-induced pyresis by 81% within 2 h of administration at a dose of 3 mg/kg and showed no effect in a fecal 51Cr excretion model of gastropathy at 100 mg/kg/day for 5 days, in contrast to lower doses of diclofenac or naproxen.	Etoricoxib	21-31	interferon regulatory factor 6	Homo sapiens	41-44
11160644-9	2001	In summary, etoricoxib represents a novel agent that selectively inhibits COX-2 with 106-fold selectivity in human whole blood assays in vitro and with the lowest potency of inhibition of COX-1 compared with other reported selective agents.	Etoricoxib	12-22	prostaglandin-endoperoxide synthase 2	Homo sapiens	74-79
11160644-9	2001	In summary, etoricoxib represents a novel agent that selectively inhibits COX-2 with 106-fold selectivity in human whole blood assays in vitro and with the lowest potency of inhibition of COX-1 compared with other reported selective agents.	Etoricoxib	12-22	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	188-193
34238176-11	2022	In addition, Etoricoxib significantly down-regulated the protein expression of interleukin 1 beta (IL-1beta), tumor necrosis factor alpha (TNFalpha), nuclear Factor-kappa B (NF-kappaB), phosphorylated nuclear Factor-kappa B (p-NF-kappaB), cyclooxygenase-2 (COX-2), and prostaglandin E2 (PGE2).	Etoricoxib	13-23	interleukin 1 beta	Rattus norvegicus	79-97
11160644-2	2001	Etoricoxib selectively inhibited COX-2 in human whole blood assays in vitro, with an IC(50) value of 1.1 +/- 0.1 microM for COX-2 (LPS-induced prostaglandin E2 synthesis), compared with an IC(50) value of 116 +/- 8 microM for COX-1 (serum thromboxane B2 generation after clotting of the blood).	Etoricoxib	0-10	interferon regulatory factor 6	Homo sapiens	131-134
11160644-2	2001	Etoricoxib selectively inhibited COX-2 in human whole blood assays in vitro, with an IC(50) value of 1.1 +/- 0.1 microM for COX-2 (LPS-induced prostaglandin E2 synthesis), compared with an IC(50) value of 116 +/- 8 microM for COX-1 (serum thromboxane B2 generation after clotting of the blood).	Etoricoxib	0-10	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	226-231
34948081-5	2021	The optimized ETO loaded NE was then investigated for its anticancer potential employing A549 lung cancer cell line via cytotoxicity, apoptotic activity, mitochondrial membrane potential activity, cell migration assay, cell cycle analysis, Caspase-3, 9, and p53 activity by ELISA and molecular biomarker analysis through RT-PCR test.	Etoricoxib	14-17	caspase 3	Homo sapiens	240-249
34948081-5	2021	The optimized ETO loaded NE was then investigated for its anticancer potential employing A549 lung cancer cell line via cytotoxicity, apoptotic activity, mitochondrial membrane potential activity, cell migration assay, cell cycle analysis, Caspase-3, 9, and p53 activity by ELISA and molecular biomarker analysis through RT-PCR test.	Etoricoxib	14-17	tumor protein p53	Homo sapiens	258-261
34540082-0	2021	Effect of Etoricoxib on miR-214 and inflammatory reaction in knee osteoarthritis patients.	Etoricoxib	10-20	microRNA 214	Homo sapiens	24-31
34540082-1	2021	PURPOSE: To explore the effect of Etoricoxib on serum miR-214 expression level and inflammatory reaction in patients with knee osteoarthritis.	Etoricoxib	34-44	microRNA 214	Homo sapiens	54-61
35453005-7	2022	Young patients, patients dealing with acute pain, or with active and/or chronic symptomatic gastritis, selective COX-2 inhibitors (celecoxib or etoricoxib) may be a better option (level of evidence 2).	Etoricoxib	144-154	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	113-118
35585779-6	2022	Rofecoxib (Vioxx) was withdrawn from the market for this reason, but the equally COX-2 selective etoricoxib has replaced it in Europe but not in the US.	Etoricoxib	97-107	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	81-86
34811370-2	2021	Here we assess the safety and immunogenicity of adjunctive vaccination with the H56:IC31 candidate and cyclooxygenase-2-inhibitor treatment (etoricoxib) in pulmonary and extra-pulmonary tuberculosis patients in a randomized open-label phase I/II clinical trial (TBCOX2, NCT02503839).	Etoricoxib	141-151	prostaglandin-endoperoxide synthase 2	Homo sapiens	103-119
35209221-1	2022	Copper oxide nanoparticles (CuO NPs) were synthesized through the coprecipitation method and used as nanocarriers for etoricoxib (selective COX-2 inhibitor drug) and montelukast (leukotriene product inhibitor drug) in combination therapy.	Etoricoxib	118-128	cytochrome c oxidase II, mitochondrial	Mus musculus	140-145
34238176-7	2022	RESULTS: Etoricoxib significantly suppressed alpha-fetoprotein (AFP) and carbohydrate antigen 19-9 (CA19.9) as liver tumor biomarkers.	Etoricoxib	9-19	alpha-fetoprotein	Rattus norvegicus	45-62
34238176-7	2022	RESULTS: Etoricoxib significantly suppressed alpha-fetoprotein (AFP) and carbohydrate antigen 19-9 (CA19.9) as liver tumor biomarkers.	Etoricoxib	9-19	alpha-fetoprotein	Rattus norvegicus	64-67
34238176-11	2022	In addition, Etoricoxib significantly down-regulated the protein expression of interleukin 1 beta (IL-1beta), tumor necrosis factor alpha (TNFalpha), nuclear Factor-kappa B (NF-kappaB), phosphorylated nuclear Factor-kappa B (p-NF-kappaB), cyclooxygenase-2 (COX-2), and prostaglandin E2 (PGE2).	Etoricoxib	13-23	interleukin 1 alpha	Rattus norvegicus	99-107
34238176-11	2022	In addition, Etoricoxib significantly down-regulated the protein expression of interleukin 1 beta (IL-1beta), tumor necrosis factor alpha (TNFalpha), nuclear Factor-kappa B (NF-kappaB), phosphorylated nuclear Factor-kappa B (p-NF-kappaB), cyclooxygenase-2 (COX-2), and prostaglandin E2 (PGE2).	Etoricoxib	13-23	tumor necrosis factor	Rattus norvegicus	110-137
34238176-11	2022	In addition, Etoricoxib significantly down-regulated the protein expression of interleukin 1 beta (IL-1beta), tumor necrosis factor alpha (TNFalpha), nuclear Factor-kappa B (NF-kappaB), phosphorylated nuclear Factor-kappa B (p-NF-kappaB), cyclooxygenase-2 (COX-2), and prostaglandin E2 (PGE2).	Etoricoxib	13-23	tumor necrosis factor	Rattus norvegicus	139-147
34238176-11	2022	In addition, Etoricoxib significantly down-regulated the protein expression of interleukin 1 beta (IL-1beta), tumor necrosis factor alpha (TNFalpha), nuclear Factor-kappa B (NF-kappaB), phosphorylated nuclear Factor-kappa B (p-NF-kappaB), cyclooxygenase-2 (COX-2), and prostaglandin E2 (PGE2).	Etoricoxib	13-23	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	239-255
34238176-11	2022	In addition, Etoricoxib significantly down-regulated the protein expression of interleukin 1 beta (IL-1beta), tumor necrosis factor alpha (TNFalpha), nuclear Factor-kappa B (NF-kappaB), phosphorylated nuclear Factor-kappa B (p-NF-kappaB), cyclooxygenase-2 (COX-2), and prostaglandin E2 (PGE2).	Etoricoxib	13-23	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	257-262
34238176-12	2022	CONCLUSION: In conclusion, the current results proved that etoricoxib possesses an anticarcinogenic effect via its antioxidant, anti-inflammatory, and modulation of NF-kappaB/COX-2/PGE2 signaling.	Etoricoxib	59-69	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	175-180
33852188-8	2021	Moreover, through the 3-month trial of oral administration of Etoricoxib, an effective response similar to that we reported previously in PHOAR2 patients was observed in PHOAD probands.	Etoricoxib	62-72	solute carrier organic anion transporter family member 2A1	Homo sapiens	138-144
34015226-0	2021	Stabilization of Etoricoxib Nanosuspension Using Acacia chundra Gum and Copolymers: Preparation, Characterization, and In Vitro Cytotoxic Study.	Etoricoxib	17-27	OTU deubiquitinase with linear linkage specificity	Homo sapiens	64-67
34015226-1	2021	Present communication deals with the stabilization of etoricoxib nanosuspension using Acacia chundra gum and its acrylamide-grafted and carboxymethylated copolymers.	Etoricoxib	54-64	OTU deubiquitinase with linear linkage specificity	Homo sapiens	101-104
33730601-5	2021	This article introduces a potential repositioning of the existing drug etoricoxib, which may inhibit cytokine storm to treat COVID-19 through reducing the activity of Cyclooxygenase-2 in the conversion of arachidonic acid to prostaglandin.	Etoricoxib	71-81	prostaglandin-endoperoxide synthase 2	Homo sapiens	167-183
33895524-6	2021	Mean number of neutrophils, and mean serum CRP and D-dimer levels were higher in Etoricoxib-treated group (P < 0.05).	Etoricoxib	81-91	C-reactive protein	Homo sapiens	43-46
33454433-2	2021	COX-2 inhibition with etoricoxib resulted in significant structural anomalies such as anophthalmia (born without one or both eyes), phocomelia (underdeveloped or truncated limbs), and gastroschisis (an opening in the abdominal wall), indicating its significance in embryogenesis.	Etoricoxib	22-32	COX2	Gallus gallus	0-5
33454433-5	2021	The compensatory increase in the activity of COX-1 observed in the etoricoxib-treated group helped to maintain the levels of PGD2, PGF2alpha, and TXB2.	Etoricoxib	67-77	COX1	Gallus gallus	45-50
33454433-5	2021	The compensatory increase in the activity of COX-1 observed in the etoricoxib-treated group helped to maintain the levels of PGD2, PGF2alpha, and TXB2.	Etoricoxib	67-77	prostaglandin D2 synthase 21kDa (brain)	Gallus gallus	125-129
33429006-5	2021	Treatment with a COX-2 selective inhibitor, etoricoxib, decreased PGE2, IL-6, MCP-1, and CLS-B formation as well as reduced aromatase protein and estrogen levels in the mammary tissue of mice fed a HSF diet.	Etoricoxib	44-54	prostaglandin-endoperoxide synthase 2	Homo sapiens	17-22
33429006-5	2021	Treatment with a COX-2 selective inhibitor, etoricoxib, decreased PGE2, IL-6, MCP-1, and CLS-B formation as well as reduced aromatase protein and estrogen levels in the mammary tissue of mice fed a HSF diet.	Etoricoxib	44-54	interleukin 6	Mus musculus	72-76
33429006-5	2021	Treatment with a COX-2 selective inhibitor, etoricoxib, decreased PGE2, IL-6, MCP-1, and CLS-B formation as well as reduced aromatase protein and estrogen levels in the mammary tissue of mice fed a HSF diet.	Etoricoxib	44-54	mast cell protease 1	Mus musculus	78-83
32912981-13	2020	CONCLUSION: Although cyclo-oxygenase-2 inhibitors and traditional non-selective NSAIDs may be equally beneficial in terms of pain relief, cyclo-oxygenase-2 inhibitors (especially etoricoxib) may confer a greater benefit.	Etoricoxib	179-189	prostaglandin-endoperoxide synthase 2	Homo sapiens	138-155
32989835-2	2020	The COX-2 inhibitor etoricoxib, in particular, was studied.	Etoricoxib	20-30	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	4-9
33468439-3	2021	Nonsteroidal anti-inflammatory drugs are one of the most common offending drug groups in FDE; however, selective cyclooxygenase-2 inhibitors, such as etoricoxib, are rarely implicated.	Etoricoxib	150-160	prostaglandin-endoperoxide synthase 2	Homo sapiens	113-129
32818660-1	2020	OBJECTIVES: The non-steroidal anti-inflammatory drug etoricoxib is the most highly selective inhibitor of cyclooxygenase-2 available (344:1) and has been approved for postoperative pain therapy following dental interventions in Europe.	Etoricoxib	53-63	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	106-122
32606658-1	2020	Aim: Etoricoxib is a selective inhibitor of COX-2 enzyme.	Etoricoxib	5-15	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	44-49
32330796-1	2020	Etoricoxib, a selective Cyclooxygenase-2 (COX-2) inhibitor, is commonly used in osteoarthritis (OA) for pain relief, however, little is known about the effects on subchondral bone.	Etoricoxib	0-10	prostaglandin-endoperoxide synthase 2	Mus musculus	24-40
32330796-1	2020	Etoricoxib, a selective Cyclooxygenase-2 (COX-2) inhibitor, is commonly used in osteoarthritis (OA) for pain relief, however, little is known about the effects on subchondral bone.	Etoricoxib	0-10	prostaglandin-endoperoxide synthase 2	Mus musculus	42-47
31360199-14	2019	Colchicine could upregulate miR-223-3p and downregulate IL-1beta in the plasma, while etoricoxib may treat AGA by upregulating miR-451a and downregulating COX-2.	Etoricoxib	86-96	microRNA 451a	Homo sapiens	127-135
32303303-1	2020	Etoricoxib, a selective inhibitor of cyclooxygenase-2, is used in the treatment of many inflammatory diseases and dental pain in humans.	Etoricoxib	0-10	prostaglandin-endoperoxide synthase 2	Homo sapiens	37-53
32382387-0	2020	RT-qPCR study of COX-1 and -2 genes in oral surgical model comparing single-dose preemptive ibuprofen and etoricoxib: A randomized clinical trialy.	Etoricoxib	106-116	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	17-29
32382387-5	2020	Results: There was a significant increase in COX-1 expression between T0 and T30 in ibuprofen (p=0.004) and etoricoxib (p=0.010) groups.	Etoricoxib	108-118	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	45-50
31495059-0	2020	The COX-2 inhibitor etoricoxib reduces experimental osteoarthritis and nociception in rats: The roles of TGF-beta1 and NGF expressions in chondrocytes.	Etoricoxib	20-30	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	4-9
31495059-0	2020	The COX-2 inhibitor etoricoxib reduces experimental osteoarthritis and nociception in rats: The roles of TGF-beta1 and NGF expressions in chondrocytes.	Etoricoxib	20-30	transforming growth factor, beta 1	Rattus norvegicus	105-114
31495059-0	2020	The COX-2 inhibitor etoricoxib reduces experimental osteoarthritis and nociception in rats: The roles of TGF-beta1 and NGF expressions in chondrocytes.	Etoricoxib	20-30	nerve growth factor	Rattus norvegicus	119-122
31495059-2	2020	Etoricoxib, a highly selective cyclooxygenase (COX)-2 inhibitor which can reduce postoperative pain after orthopedic surgery.	Etoricoxib	0-10	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	31-53
31495059-8	2020	Immunohistochemical analysis was performed to examine the effect of etoricoxib on the expression of transforming growth factor-beta (TGF-beta) and nerve growth factor (NGF) in articular cartilage chondrocytes.	Etoricoxib	68-78	transforming growth factor, beta 1	Rattus norvegicus	133-141
31495059-8	2020	Immunohistochemical analysis was performed to examine the effect of etoricoxib on the expression of transforming growth factor-beta (TGF-beta) and nerve growth factor (NGF) in articular cartilage chondrocytes.	Etoricoxib	68-78	nerve growth factor	Rattus norvegicus	147-166
31495059-8	2020	Immunohistochemical analysis was performed to examine the effect of etoricoxib on the expression of transforming growth factor-beta (TGF-beta) and nerve growth factor (NGF) in articular cartilage chondrocytes.	Etoricoxib	68-78	nerve growth factor	Rattus norvegicus	168-171
31495059-11	2020	Moreover, etoricoxib attenuated NGF expression, but increased TGF-beta expression, in OA-affected cartilage.	Etoricoxib	10-20	nerve growth factor	Rattus norvegicus	32-35
31495059-11	2020	Moreover, etoricoxib attenuated NGF expression, but increased TGF-beta expression, in OA-affected cartilage.	Etoricoxib	10-20	transforming growth factor, beta 1	Rattus norvegicus	62-70
31495059-12	2020	CONCLUSIONS: Oral etoricoxib in a rat OA model (1) attenuates the development of OA, (2) concomitantly reduces nociception, and (3) modulates chondrocyte metabolism, possibly by inhibiting NGF expression and increasing TGF-beta expression.	Etoricoxib	18-28	nerve growth factor	Rattus norvegicus	189-192
31495059-12	2020	CONCLUSIONS: Oral etoricoxib in a rat OA model (1) attenuates the development of OA, (2) concomitantly reduces nociception, and (3) modulates chondrocyte metabolism, possibly by inhibiting NGF expression and increasing TGF-beta expression.	Etoricoxib	18-28	transforming growth factor, beta 1	Rattus norvegicus	219-227
31190596-1	2019	Background: Etoricoxib is a second-generation cyclooxygenase-2-inhibitor approved in 2012 for short-term treatment of pain associated with dental surgery.	Etoricoxib	12-22	prostaglandin-endoperoxide synthase 2	Homo sapiens	46-62
31004291-7	2019	After being treated with etoricoxib, the serum potassium level of the patient increased rapidly to the normal range which corresponded with the reduction in his serum PGE2 and PE2 metabolite (PGEM) levels.	Etoricoxib	25-35	ETS2 repressor factor	Homo sapiens	176-179
31360199-14	2019	Colchicine could upregulate miR-223-3p and downregulate IL-1beta in the plasma, while etoricoxib may treat AGA by upregulating miR-451a and downregulating COX-2.	Etoricoxib	86-96	prostaglandin-endoperoxide synthase 2	Homo sapiens	155-160
30080442-2	2019	Here, the molecular interaction between purified human hemoglobin (HHb), a major heme protein and etoricoxib, a cyclooxygenase-2 inhibitor was studied by various spectroscopic, calorimetric, and molecular modeling techniques.	Etoricoxib	98-108	prostaglandin-endoperoxide synthase 2	Homo sapiens	112-128
30970055-1	2019	In the present study we compared the effects of the selective COX-2 inhibitor etoricoxib with those of the classical non-selective NSAID diclofenac on the inflammatory process and alveolar bone loss in an experimental model of periodontitis in rats.	Etoricoxib	78-88	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	62-67
30983880-0	2019	Effects of the Highly COX-2-Selective Analgesic NSAID Etoricoxib on Human Periodontal Ligament Fibroblasts during Compressive Orthodontic Mechanical Strain.	Etoricoxib	54-64	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	22-27
30983880-2	2019	The highly COX-2-selective NSAID etoricoxib has a favorable systemic side effect profile and high analgesic efficacy, particularly for orthodontic pain.	Etoricoxib	33-43	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	11-16
30983880-3	2019	In this in vitro study, we investigated possible side effects of two clinically relevant etoricoxib concentrations on the expression pattern of mechanically strained hPDL fibroblasts and associated osteoclastogenesis in a model of simulated orthodontic compressive strain occurring during orthodontic tooth movement.	Etoricoxib	89-99	programmed cell death 1	Homo sapiens	166-170
30983880-7	2019	Etoricoxib at 3.29 muM and 5.49 muM significantly inhibited PG-E2 synthesis, but not COX-2 and IL-6 gene expression nor RANK-L-/OPG-mediated osteoclastogenesis or angiogenesis (VEGF-A).	Etoricoxib	0-10	latexin	Homo sapiens	19-22
30983880-7	2019	Etoricoxib at 3.29 muM and 5.49 muM significantly inhibited PG-E2 synthesis, but not COX-2 and IL-6 gene expression nor RANK-L-/OPG-mediated osteoclastogenesis or angiogenesis (VEGF-A).	Etoricoxib	0-10	vascular endothelial growth factor A	Homo sapiens	177-183
30983880-10	2019	Clinically dosed etoricoxib, that is, a highly selective COX-2 inhibition, did not have substantial effects on hPDL fibroblast-mediated periodontal inflammation, extracellular matrix remodeling, RANK-L/OPG expression, and osteoclastogenesis during simulated orthodontic compressive strain.	Etoricoxib	17-27	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	57-62
30048759-0	2018	Effects of the highly COX-2-selective analgesic NSAID etoricoxib on the rate of orthodontic tooth movement and cranial growth.	Etoricoxib	54-64	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	22-27
29655084-6	2018	The results indicated that MTL-1 had a significant anti-epileptogenic effect in PTZ kindled rats as compared to Etoricoxib (ETX) and PTZ alone treated group.	Etoricoxib	112-122	metallothionein 1X pseudogene 1	Homo sapiens	27-32
29655084-6	2018	The results indicated that MTL-1 had a significant anti-epileptogenic effect in PTZ kindled rats as compared to Etoricoxib (ETX) and PTZ alone treated group.	Etoricoxib	124-127	metallothionein 1X pseudogene 1	Homo sapiens	27-32
29239930-0	2018	Primary Hypertrophic Osteoarthropathy With SLCO2A1 Mutation in a Chinese Patient Successfully Treated With Etoricoxib.	Etoricoxib	107-117	solute carrier organic anion transporter family member 2A1	Homo sapiens	43-50
26875533-0	2019	Successful treatment of pachydermoperiostosis with etoricoxib in a patient with a homozygous splice-site mutation in the SLCO2A1 gene.	Etoricoxib	51-61	solute carrier organic anion transporter family member 2A1	Homo sapiens	121-128
30636337-10	2019	Since its introduction in 2003, the use of etoricoxib, a newer selective COX-2 inhibitor, increased in all countries except Denmark, with highest sales in Finland (6.7 DDD/1000 inhabitants/day in 2016).	Etoricoxib	43-53	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	73-78
30048759-2	2018	The highly COX-2-selective NSAID etoricoxib has shown a favorable side effect profile and excellent analgesic efficacy, particularly for dental and orthodontic pain, surpassing the current standard analgesic in orthodontics, acetaminophen.	Etoricoxib	33-43	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	11-16
29670468-8	2018	Results: SAA-stimulated levels of released IL-6, IL-8, and sVCAM-1 from HCAEC were significantly attenuated by methotrexate, fluvastatin, and etoricoxib.	Etoricoxib	142-152	serum amyloid A1 cluster	Homo sapiens	9-12
28954205-1	2018	Etoricoxib is a selective cyclooxygenase-2 inhibitor, with a lower risk of gastrointestinal toxicity compared to traditional nonsteroidal anti-inflammatory drugs (NSAIDs).	Etoricoxib	0-10	prostaglandin-endoperoxide synthase 2	Homo sapiens	26-42
29670468-8	2018	Results: SAA-stimulated levels of released IL-6, IL-8, and sVCAM-1 from HCAEC were significantly attenuated by methotrexate, fluvastatin, and etoricoxib.	Etoricoxib	142-152	interleukin 6	Homo sapiens	43-47
29670468-8	2018	Results: SAA-stimulated levels of released IL-6, IL-8, and sVCAM-1 from HCAEC were significantly attenuated by methotrexate, fluvastatin, and etoricoxib.	Etoricoxib	142-152	C-X-C motif chemokine ligand 8	Homo sapiens	49-53
32185252-1	2017	Objectives: To determine the impact of celecoxib and etoricoxib therapy on serum and synovial fluid levels of IL-1beta, IL-6, TNF-alpha, sTNFR1, sTNFR2 and IL-1Ra in patients with inflammatory arthritis.	Etoricoxib	53-63	interleukin 1 alpha	Homo sapiens	110-118
28778815-2	2017	This study investigated whether 14 days of the selective Cox-2 inhibitor etoricoxib (60 mg/day) would modify self-report of pain intensity and quality, and physical measures of hyperalgesia and function in individuals with knee OA.	Etoricoxib	73-83	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	57-62
28464042-4	2017	Patients in each of the two study groups were randomized to receive 90 mg qd of the cyclooxygenase-2 inhibitor etoricoxib for six months, two weeks or to a control arm, respectively.	Etoricoxib	111-121	prostaglandin-endoperoxide synthase 2	Homo sapiens	84-100
28464042-7	2017	In ART-naive patients, etoricoxib reduced the density of the activation marker CD38 in multiple CD8+ T cell subsets, improved Gag-specific T cell responses, and reduced in vitro plasma thrombin generation, while no effects were seen on plasma markers of inflammation or tryptophan metabolism.	Etoricoxib	23-33	CD8a molecule	Homo sapiens	96-99
28464042-7	2017	In ART-naive patients, etoricoxib reduced the density of the activation marker CD38 in multiple CD8+ T cell subsets, improved Gag-specific T cell responses, and reduced in vitro plasma thrombin generation, while no effects were seen on plasma markers of inflammation or tryptophan metabolism.	Etoricoxib	23-33	coagulation factor II, thrombin	Homo sapiens	185-193
28610818-8	2017	A significant reduction in TNF-alpha concentration from time 0" to time 30" was seen for ibuprofen (P=0.001) and etoricoxib (P=0.016).	Etoricoxib	113-123	tumor necrosis factor	Homo sapiens	27-36
28425581-9	2017	Treatment with etoricoxib, a selective cyclooxygenase-2 inhibitor, was proved to be beneficial and safe.	Etoricoxib	15-25	prostaglandin-endoperoxide synthase 2	Homo sapiens	39-55
28425581-13	2017	For the first time, we systematically investigated the biochemical and clinical differences between PHOAR1 and PHOAR2, and prospectively showed the positive efficacy and safety of etoricoxib for PHO patients.	Etoricoxib	180-190	15-hydroxyprostaglandin dehydrogenase	Homo sapiens	100-106
28425581-13	2017	For the first time, we systematically investigated the biochemical and clinical differences between PHOAR1 and PHOAR2, and prospectively showed the positive efficacy and safety of etoricoxib for PHO patients.	Etoricoxib	180-190	solute carrier organic anion transporter family member 2A1	Homo sapiens	111-117
28676124-10	2017	Another finding was the concomitant use of COX-2 inhibitors (Etoricoxib or Celecoxib) and PPIs.	Etoricoxib	61-71	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	43-48
32185252-8	2017	In the etoricoxib treated group synovial fluid IL-6 concentration was significantly decreased after treatment (p=0.019).	Etoricoxib	7-17	interleukin 6	Homo sapiens	47-51
32185252-9	2017	Correlating the study drugs penetration index with the change of cytokines and their receptors levels, positive correlation was found with the reduction of synovial fluid IL-1beta for the celecoxib (p=0.032) and with the increase of synovial fluid sTNFR1 for the etoricoxib group (p=0.028).	Etoricoxib	263-273	interleukin 1 alpha	Homo sapiens	171-179
28057325-0	2017	Design, synthesis and biological screening of some novel celecoxib and etoricoxib analogs with promising COX-2 selectivity, anti-inflammatory activity and gastric safety profile.	Etoricoxib	71-81	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	105-110
28210513-0	2017	Seizure following the Use of the COX-2 Inhibitor Etoricoxib.	Etoricoxib	49-59	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	33-38
28210513-4	2017	Neuroimaging and blood samples studies did not evidence alterations, but a careful pharmacological history revealed that the patient had taken the COX-2 inhibitor etoricoxib to treat lumbago few days before the onset of clinical symptoms.	Etoricoxib	163-173	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	147-152
27576781-1	2016	WHAT IS KNOWN AND OBJECTIVE: Etoricoxib is a non-steroidal anti-inflammatory drug (NSAID) that inhibits the inducible cyclooxygenase (COX-2) with a good safety profile.	Etoricoxib	29-39	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	134-139
28228088-2	2017	Several compounds having selective COX-2 inhibitors such as SC-558, Celecoxib, Rofecoxib, Valdecoxib and Etoricoxib are marketed as new generation NSAIDs and block the production of prostaglandins (PGs) in inflammatory cells.	Etoricoxib	105-115	cox2	Gossypium hirsutum	35-40
28884717-7	2017	A drug of choice in case of intensive pain and marked nociceptive component are highly effective and safe nonsteroidal anti-inflammatory drugs, in particular etoricoxib (Arcoxia), a selective COX-2 inhibitor.	Etoricoxib	158-168	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	192-197
28884717-7	2017	A drug of choice in case of intensive pain and marked nociceptive component are highly effective and safe nonsteroidal anti-inflammatory drugs, in particular etoricoxib (Arcoxia), a selective COX-2 inhibitor.	Etoricoxib	170-177	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	192-197
27007068-0	2016	Evidence for a central mode of action for etoricoxib (COX-2 inhibitor) in patients with painful knee osteoarthritis.	Etoricoxib	42-52	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	54-59
27779319-5	2016	Their IC50 values against the COX-2 enzyme were 0.67 and 0.85 microM, respectively, which is more potent than etoricoxib.	Etoricoxib	110-120	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	30-35
27502582-0	2016	Evaluation of two doses of etoricoxib, a COX-2 selective non-steroidal anti-inflammatory drug (NSAID), in the treatment of Rheumatoid Arthritis in a double-blind, randomized controlled trial.	Etoricoxib	27-37	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	41-46
27502582-2	2016	Etoricoxib is a COX-2 selective NSAID that has demonstrated efficacy in the treatment of RA at a dose of 90 mg.	Etoricoxib	0-10	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	16-21
27007068-1	2016	The COX-2 inhibitor etoricoxib modulates the peripheral and central nociceptive mechanisms in animals.	Etoricoxib	20-30	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	4-9
26838881-2	2016	Etoricoxib (COX-2 inhibitor), a highly hydrophobic drug was chosen as a model drug for the study.	Etoricoxib	0-10	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	12-17
26593212-9	2016	RESULTS: Co-administration of ETO with APE and pure AN decreased systemic exposure level of each compound in vivo.	Etoricoxib	30-33	apurinic/apyrimidinic endodeoxyribonuclease 1	Rattus norvegicus	39-42
26593212-10	2016	The Cmax, AUC, t1/2 of ETO was decreased whereas Vd and CL of ETO was increased significantly after co-administration of ETO with pure AN and APE.	Etoricoxib	62-65	apurinic/apyrimidinic endodeoxyribonuclease 1	Rattus norvegicus	142-145
26593212-10	2016	The Cmax, AUC, t1/2 of ETO was decreased whereas Vd and CL of ETO was increased significantly after co-administration of ETO with pure AN and APE.	Etoricoxib	62-65	apurinic/apyrimidinic endodeoxyribonuclease 1	Rattus norvegicus	142-145
26593212-11	2016	In pharmacodynamic study, ETO alone and ETO+APE (10+200mg/kg) groups exhibited significant synergistic anti-arthritic activity as compared to groups ETO+AN, APE and AN alone.	Etoricoxib	40-44	apurinic/apyrimidinic endodeoxyribonuclease 1	Rattus norvegicus	157-160
25701797-0	2015	Antiepileptogenic effects of the selective COX-2 inhibitor etoricoxib, on the development of spontaneous absence seizures in WAG/Rij rats.	Etoricoxib	59-69	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	43-48
26857505-9	2016	Administration of etoricoxib in cAD rats resulted in recovery of memory impairments, neurodegeneration and neuroinflammation in hippocampus and inhibition of cox-2 and PGE2 levels in hippocampus.	Etoricoxib	18-28	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	158-163
26689653-2	2016	In this work, we explored Etoricoxib (COX-2 inhibitor)-loaded Poly caprolactone (PCL) microparticles (MPs) as a potential IA-DDS.	Etoricoxib	26-36	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	38-43
26548623-7	2015	Some other COX-2 inhibitors, such as, apricoxib and etoricoxib are under critical investigation currently.	Etoricoxib	52-62	prostaglandin-endoperoxide synthase 2	Homo sapiens	11-16
26904451-2	2015	Etoricoxib is a second-generation cox-2 inhibitor and as its use increases so do the reports of side effects.	Etoricoxib	0-10	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	34-39
26049010-6	2015	Our results showed that the non-selective acidic NSAIDs ibuprofen and diclofenac induced AMPK activation similar to aspirin while the COX-2 selective drug etoricoxib and the non-opioid analgesic paracetamol, both drugs have no acidic structure, failed to activate AMPK.	Etoricoxib	155-165	cytochrome c oxidase II, mitochondrial	Mus musculus	134-139
26100666-7	2015	Indomethacin (COX-1/COX-2 inhibitor) or etoricoxib (COX-2 inhibitor) partially diminished edema (around 20%) in PmV-injected mice.	Etoricoxib	40-50	cytochrome c oxidase II, mitochondrial	Mus musculus	52-57
26857505-7	2016	administration of 3 different doses of etoricoxib, a cox 2 inhibitor.	Etoricoxib	39-49	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	53-58
25828692-2	2016	The pre-emptive and postoperative analgesic effects of the cyclooxygenase-2 inhibitor etoricoxib have been investigated using a 2 x 2 factorial trial design.	Etoricoxib	86-96	prostaglandin-endoperoxide synthase 2	Homo sapiens	59-75
26880859-3	2016	Therefore, the present study was designed to investigate the role of cox-2 on the anxiety behavior (response to novelty in an elevated open field space) of cAD by inhibiting it with three different doses (10, 20, and 30 mg) of etoricoxib (a cox-2 blocker) in two time points (14 and 21 days).	Etoricoxib	227-237	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	69-74
27372432-3	2016	METHODS: Sixteen subjects with mild allergic asthma were recruited to a two-period cross-over study: one treatment period with the selective COX-2 inhibitor etoricoxib and one without.	Etoricoxib	157-167	prostaglandin-endoperoxide synthase 2	Homo sapiens	141-146
27372432-10	2016	CONCLUSIONS: Short-term treatment with the COX-2 inhibitor etoricoxib had a minor impact on T-cell responses, supporting its safe use also in subjects exposed to triggers of lymphocyte activation.	Etoricoxib	59-69	prostaglandin-endoperoxide synthase 2	Homo sapiens	43-48
25701797-5	2015	We studied whether early long-term treatment (17 consecutive weeks starting from 45 days postnatal age) with the non-steroidal anti-inflammatory drug etoricoxib (10 mg/kg/day per os), a selective COX-2 inhibitor, was able to prevent/reduce the development of absence seizures in WAG/Rij rats, a recognized animal model of absence epilepsy and epileptogenesis.	Etoricoxib	150-160	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	196-201
25660085-0	2015	Anticonvulsant activity of the cyclooxygenase-2 (COX-2) inhibitor etoricoxib in pentylenetetrazole-kindled rats is associated with memory impairment.	Etoricoxib	66-76	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	31-47
25660085-0	2015	Anticonvulsant activity of the cyclooxygenase-2 (COX-2) inhibitor etoricoxib in pentylenetetrazole-kindled rats is associated with memory impairment.	Etoricoxib	66-76	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	49-54
25660085-2	2015	In the present study, the effect of the selective COX-2 inhibitor etoricoxib on seizures, oxidative stress, and learning and memory was studied.	Etoricoxib	66-76	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	50-55
25340915-4	2014	COX-2 inhibitors include drugs such as celecoxib, rofecoxib, valdecoxib, etoricoxib, and lumiracoxib.	Etoricoxib	73-83	prostaglandin-endoperoxide synthase 2	Homo sapiens	0-5
26236425-9	2015	RESULTS: Etoricoxib in 50 and 100 mg/kg doses changed the levels of oxidant/antioxidant parameters such as MDA, MPO, tGSH, GSHRd, GST, SOD, NO, and 8-OH/Gua in favour of antioxidants.	Etoricoxib	9-19	myeloperoxidase	Rattus norvegicus	112-115
26236425-10	2015	Furthermore, etoricoxib prevented increase of COX-2 gene expression and ALT and AST levels.	Etoricoxib	13-23	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	46-51
25029569-1	2014	AIM: The present meta-analysis attempted to assess whether an unfavourable cardiovascular risk profile could be identified in the case of two COX2 selective inhibitors (COXIBs), namely celecoxib and etoricoxib.	Etoricoxib	199-209	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	142-146
25068826-7	2014	Etoricoxib reduced, in a dose-dependent manner, levels of MDA, MPO and COX-2 that normally rise with I/R in rat kidney tissues.	Etoricoxib	0-10	myeloperoxidase	Rattus norvegicus	63-66
25068826-7	2014	Etoricoxib reduced, in a dose-dependent manner, levels of MDA, MPO and COX-2 that normally rise with I/R in rat kidney tissues.	Etoricoxib	0-10	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	71-76
25068826-10	2014	Furthermore, etoricoxib significantly decreased the caspase-3 gene expression which increased with I/R.	Etoricoxib	13-23	caspase 3	Rattus norvegicus	52-61
25229174-1	2014	Etoricoxib is a newer cyclooxygenase (COX)-2 inhibitor anti-inflammatory drug with a favorable safety profile.	Etoricoxib	0-10	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	22-44
24888933-1	2014	AIM: This study is a biochemical investigation of the effect of etoricoxib, a selective cyclooxygenase (COX)-2 inhibitor, on ischemia/reperfusion (I/R) injury experimentally induced in rat ovaries.	Etoricoxib	64-74	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	88-110
24461582-3	2014	OBJECTIVE: To determine the effects of the selective COX-2 inhibitor, etoricoxib, on allergen-induced bronchoconstriction in asthmatic subjects.	Etoricoxib	70-80	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	53-58
24469906-7	2014	The local COX-2 inhibition by etoricoxib was most pronounced for PGD2.	Etoricoxib	30-40	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	10-15
24469906-9	2014	CONCLUSIONS: Doses of 50 mg lumiracoxib and 90 mg etoricoxib produced similar maximum inhibition of systemic COX-2 function whereas 50 mg lumiracoxib was ineffective in producing local COX-2 inhibition.	Etoricoxib	50-60	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	109-114
24135073-11	2014	In the jejunum, etoricoxib or celecoxib did not modify such parameters, whereas in the ileum, etoricoxib, but not celecoxib, increased both MDA and MPO levels.	Etoricoxib	94-104	myeloperoxidase	Rattus norvegicus	148-151
24383977-2	2013	Etoricoxib, a cox-2 inhibitor NSAID, has been shown to be a safe alternative in these patients.	Etoricoxib	0-10	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	14-19
24352312-1	2013	AIMS: Etoricoxib is a second-generation selective COX-2 inhibitor.	Etoricoxib	6-16	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	50-55
21618455-11	2011	The selective cyclooxygenase 2 (COX-2) inhibitor etoricoxib was a more potent inductor of LUF syndrome than nonselective COX inhibitors.	Etoricoxib	49-59	prostaglandin-endoperoxide synthase 2	Homo sapiens	14-30
23652751-0	2013	Increased risk for complications after colorectal surgery with selective cyclo-oxygenase 2 inhibitor etoricoxib.	Etoricoxib	101-111	prostaglandin-endoperoxide synthase 2	Homo sapiens	73-90
23126318-4	2012	Etoricoxib is a specific cyclooxygenase 2 inhibitor with strong anti-inflammatory effects and a favorable pharmacokinetic profile for the management of inflammatory disorders.	Etoricoxib	0-10	prostaglandin-endoperoxide synthase 2	Homo sapiens	25-41
22681911-0	2012	Angiostatic role of the selective cyclooxygenase-2 inhibitor etoricoxib (MK0663) in experimental lung cancer.	Etoricoxib	61-71	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	34-50
22681911-0	2012	Angiostatic role of the selective cyclooxygenase-2 inhibitor etoricoxib (MK0663) in experimental lung cancer.	Etoricoxib	73-79	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	34-50
23265037-1	2012	BACKGROUND: Etoricoxib, a selective Cox-2 inhibitor has been found to be effective in the management of acute pain.	Etoricoxib	12-22	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	36-41
21848948-3	2012	Etoricoxib, a Cox-2 inhibitor with a 22-hour half-life, has been shown effective in preventing fasting headache when taken just prior to the 25-hour Yom Kippur fast.	Etoricoxib	0-10	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	14-19
21701788-10	2012	Besides, improving cognitive dysfunction, chronic administration of highly selective cyclooxygenase-1 and/or cyclooxygenase-2 inhibitors (valeryl salicylate and etoricoxib, respectively), but not cyclooxygenase-3 inhibitor (phenacetin), significantly reduced elevated malondialdehyde, nitrite levels, and restored reduced glutathione and superoxide dismutase levels.	Etoricoxib	161-171	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	109-125
22814015-13	2012	However, etoricoxib which is a COX-2 specific inhibitor, was found to be more effective than the traditional NSAID, indomethacin.	Etoricoxib	9-19	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	31-36
22882551-1	2013	BACKGROUND: Etoricoxib, a selective inhibitor of cyclooxygenase 2, is increasingly used in pain relief.	Etoricoxib	12-22	prostaglandin-endoperoxide synthase 2	Homo sapiens	49-65
23489008-4	2013	These results demonstrate that COX-2 dependent mechanisms play a significant role in blood pressure regulation, and etoricoxib-induced COX-2 inhibition blunts the therapeutic effect of different classes of antihypertensives in this mineralocorticoid volume expansion model of hypertension.	Etoricoxib	116-126	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	135-140
23964558-2	2013	OBJECTIVE: To evaluate tolerability to etoricoxib, a second-generation COX-2 inhibitor with high in vitro selectivity for COX-2 in patients with AERD.	Etoricoxib	39-49	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	71-76
23964558-2	2013	OBJECTIVE: To evaluate tolerability to etoricoxib, a second-generation COX-2 inhibitor with high in vitro selectivity for COX-2 in patients with AERD.	Etoricoxib	39-49	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	122-127
23964558-7	2013	CONCLUSIONS: The highly selective COX-2 inhibitor etoricoxib was tolerated in most but not all patients tested.	Etoricoxib	50-60	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	34-39
22991065-0	2013	Role of cytokines in experimentally induced lung cancer and chemoprevention by COX-2 selective inhibitor, etoricoxib.	Etoricoxib	106-116	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	79-84
22991065-1	2013	This study explored the role of pro- and anti-inflammatory cytokines in dimethyl benz(a)anthracene (DMBA)-induced lung cancer and its subsequent correction with a COX-2 inhibitory NSAID, etoricoxib.	Etoricoxib	187-197	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	163-168
22991065-3	2013	The study of pro-inflammatory cytokines like IL-1beta, TNF-alpha, and IFN-gamma revealed their upregulation by DMBA administration and restoration of their levels toward normal by the treatment with etoricoxib, while the anti-inflammatory cytokine IL-2 was found to be down-regulated with carcinogen administration and corrected with etoricoxib treatment.	Etoricoxib	199-209	interleukin 1 beta	Rattus norvegicus	45-53
22991065-3	2013	The study of pro-inflammatory cytokines like IL-1beta, TNF-alpha, and IFN-gamma revealed their upregulation by DMBA administration and restoration of their levels toward normal by the treatment with etoricoxib, while the anti-inflammatory cytokine IL-2 was found to be down-regulated with carcinogen administration and corrected with etoricoxib treatment.	Etoricoxib	199-209	tumor necrosis factor	Rattus norvegicus	55-64
22991065-3	2013	The study of pro-inflammatory cytokines like IL-1beta, TNF-alpha, and IFN-gamma revealed their upregulation by DMBA administration and restoration of their levels toward normal by the treatment with etoricoxib, while the anti-inflammatory cytokine IL-2 was found to be down-regulated with carcinogen administration and corrected with etoricoxib treatment.	Etoricoxib	199-209	interferon gamma	Rattus norvegicus	70-79
22991065-3	2013	The study of pro-inflammatory cytokines like IL-1beta, TNF-alpha, and IFN-gamma revealed their upregulation by DMBA administration and restoration of their levels toward normal by the treatment with etoricoxib, while the anti-inflammatory cytokine IL-2 was found to be down-regulated with carcinogen administration and corrected with etoricoxib treatment.	Etoricoxib	199-209	interleukin 2	Rattus norvegicus	248-252
22991065-3	2013	The study of pro-inflammatory cytokines like IL-1beta, TNF-alpha, and IFN-gamma revealed their upregulation by DMBA administration and restoration of their levels toward normal by the treatment with etoricoxib, while the anti-inflammatory cytokine IL-2 was found to be down-regulated with carcinogen administration and corrected with etoricoxib treatment.	Etoricoxib	334-344	interferon gamma	Rattus norvegicus	70-79
22582102-11	2012	CONCLUSION: The current study estimated the efficacy of acetaminophen, nsNSAIDs, and COX-2 selective NSAIDs in OA and found that etoricoxib 30 mg is likely to result in the greatest improvements in pain and physical function.	Etoricoxib	129-139	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	85-90
21905970-1	2011	OBJECTIVE: To further assess the clinically active dose range of etoricoxib, a COX-2 selective inhibitor, in rheumatoid arthritis (RA).	Etoricoxib	65-75	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	79-84
21618455-11	2011	The selective cyclooxygenase 2 (COX-2) inhibitor etoricoxib was a more potent inductor of LUF syndrome than nonselective COX inhibitors.	Etoricoxib	49-59	prostaglandin-endoperoxide synthase 2	Homo sapiens	32-37
21980265-12	2011	In pair-wise comparisons, etoricoxib had a higher RR than ibuprofen, RRR = 1.68 (99% CI 1.14, 2.49), and naproxen, RRR = 1.75 (1.16, 2.64); etodolac was not significantly different from naproxen and ibuprofen.	Etoricoxib	26-36	dishevelled binding antagonist of beta catenin 3	Homo sapiens	69-76
21235334-2	2011	This study was conducted to evaluate the clinical efficacy of two selective cyclooxygenase-2 inhibitors, celecoxib and etoricoxib, on pain prevention after periodontal surgery.	Etoricoxib	119-129	prostaglandin-endoperoxide synthase 2	Homo sapiens	76-92
21539467-9	2011	In a control experiment, patients (n = 6) treated with the selective COX-2 inhibitor etoricoxib (90 mg/day) for 8 weeks showed no changes in the number of pMPs, eMPs, and EPCs and in FMD.	Etoricoxib	85-95	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	69-74
21457143-0	2011	Inhibitory effect of selective cyclooxygenase-2 inhibitor etoricoxib on human organic anion transporter 3 (hOAT3).	Etoricoxib	58-68	prostaglandin-endoperoxide synthase 2	Homo sapiens	31-47
21457143-0	2011	Inhibitory effect of selective cyclooxygenase-2 inhibitor etoricoxib on human organic anion transporter 3 (hOAT3).	Etoricoxib	58-68	solute carrier family 22 member 8	Homo sapiens	78-105
21457143-0	2011	Inhibitory effect of selective cyclooxygenase-2 inhibitor etoricoxib on human organic anion transporter 3 (hOAT3).	Etoricoxib	58-68	solute carrier family 22 member 8	Homo sapiens	107-112
21457143-3	2011	In this study, we evaluated the inhibitory effects of selective cyclooxygenase-2 inhibitor etoricoxib on hOAT3 by uptake experiments using Xenopus laevis oocytes.	Etoricoxib	91-101	prostaglandin-endoperoxide synthase 2	Homo sapiens	64-80
21457143-3	2011	In this study, we evaluated the inhibitory effects of selective cyclooxygenase-2 inhibitor etoricoxib on hOAT3 by uptake experiments using Xenopus laevis oocytes.	Etoricoxib	91-101	solute carrier family 22 member 8	Homo sapiens	105-110
21457143-4	2011	The injection of hOAT3 cRNA stimulated the uptake of methotrexate into the oocytes, and its transport was inhibited by etoricoxib.	Etoricoxib	119-129	solute carrier family 22 member 8	Homo sapiens	17-22
21457143-5	2011	Etoricoxib inhibited estrone sulfate uptake by hOAT3 dose dependently, and the 50% inhibitory concentration was estimated to be 9.8 microM.	Etoricoxib	0-10	solute carrier family 22 member 8	Homo sapiens	47-52
21457143-6	2011	Eadie-Hofstee plot analysis showed that etoricoxib inhibited hOAT3 in a competitive manner.	Etoricoxib	40-50	solute carrier family 22 member 8	Homo sapiens	61-66
21457143-7	2011	These findings show that etoricoxib has inhibitory effect on hOAT3, and that the potential is comparable to that of traditional NSAIDs.	Etoricoxib	25-35	solute carrier family 22 member 8	Homo sapiens	61-66
21332932-0	2011	Predictors of response to cyclo-oxygenase-2 inhibitors in osteoarthritis: pooled results from two identical trials comparing etoricoxib, celecoxib, and placebo.	Etoricoxib	125-135	prostaglandin-endoperoxide synthase 2	Homo sapiens	26-43
21441618-0	2011	Heme oxygenase/carbon monoxide-biliverdin pathway may be involved in the antinociceptive activity of etoricoxib, a selective COX-2 inhibitor.	Etoricoxib	101-111	prostaglandin-endoperoxide synthase 2	Mus musculus	125-130
21635885-2	2011	Cyclooxygenase-2 mRNA has been shown to be up-regulated after stroke and also the time window of its expression extends from 4 to 12 h. The objective of this study was to elucidate the protective effect of Etoricoxib (a selective Cyclooxygenase-2 inhibitor) against transient middle cerebral artery occlusion induced behavioral, biochemical and histological alterations.	Etoricoxib	206-216	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	0-16
21635885-2	2011	Cyclooxygenase-2 mRNA has been shown to be up-regulated after stroke and also the time window of its expression extends from 4 to 12 h. The objective of this study was to elucidate the protective effect of Etoricoxib (a selective Cyclooxygenase-2 inhibitor) against transient middle cerebral artery occlusion induced behavioral, biochemical and histological alterations.	Etoricoxib	206-216	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	230-246
21441618-12	2011	The analgesic effect of etoricoxib was at least partially dependent on the participation of the HO-1/BVD/CO pathway.	Etoricoxib	24-34	heme oxygenase 1	Mus musculus	96-107
21308296-4	2010	Ketorolac is a non-selective NSAID which, at low doses, has a preferential COX-1 inhibitory effect and etoricoxib is a new selective COX-2 inhibitor.	Etoricoxib	103-113	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	133-138
20349107-0	2010	The selective COX-2 inhibitor Etoricoxib reduces acute inflammatory markers in a model of neurogenic laryngitis but loses its efficacy with prolonged treatment.	Etoricoxib	30-40	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	14-19
20039959-5	2010	We hypothesized that etoricoxib, another Cox-2 inhibitor with a longer half-life, would also be effective in preventing fasting headache.	Etoricoxib	21-31	prostaglandin-endoperoxide synthase 2	Homo sapiens	41-46
20349107-3	2010	The NGI animals were divided into three groups: (1) treated with COX-2 inhibitor Etoricoxib, (2) vehicle and (3) non-intubated animals.	Etoricoxib	81-91	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	65-70
20349107-8	2010	RESULTS: Treatment for 1 week with Etoricoxib attenuated the CGRP-IR fibre depletion, the COX-2-IR increased cell number and the TNF-alpha and COX-2 mRNA increased levels induced by NGI.	Etoricoxib	35-45	calcitonin-related polypeptide alpha	Rattus norvegicus	61-65
20678677-3	2010	OBJECTIVE: The aim of this study was to assess the annual incidence of and identify the risk factors for clinical upper GI events in chronic COX-2 inhibitor (celecoxib and etoricoxib) users.	Etoricoxib	172-182	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	141-146
21373319-9	2010	Non-steroidal analgesics and other COX-2 inhibitors (rofecoxib and celecoxib) have been known to precipitate renal failure and hyperkalemia specially in patients at risk for the same; although not unexpected, this may be the first reported case of life-threatening hyperkalemia precipitated by etoricoxib in a previously stable patient having increased risk of renal failure and hyperkalemia.	Etoricoxib	294-304	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	35-40
20584877-2	2010	In the present prospective, randomized, double-blind study we compared pain management with a selective (COX-2) inhibitor (etoricoxib) with pain management using sustained-release tramadol after elective hallux valgus surgery.	Etoricoxib	123-133	prostaglandin-endoperoxide synthase 2	Homo sapiens	105-110
20349107-10	2010	CONCLUSIONS: Etoricoxib is effective in neurogenic laryngitis for limited periods of administration, indicating that selective COX-2 inhibitors should be evaluated in the future.	Etoricoxib	13-23	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	127-132
20678677-4	2010	METHODS: A prospective, hospital-based, observational cohort study was conducted in patients taking COX-2 inhibitors (celecoxib or etoricoxib) without comorbidity.	Etoricoxib	131-141	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	100-105
20440209-9	2010	Protein expression of antiapoptotic protein Bcl-2 was also studied in colonic mucosa and was found high in the DMH-treated group and low in DMH+etoricoxib treated animals.	Etoricoxib	144-154	BCL2, apoptosis regulator	Rattus norvegicus	44-49
20356104-2	2010	This protocol was applied in the synthesis of etoricoxib, talnetant and a P-selectin inhibitor.	Etoricoxib	46-56	selectin P	Homo sapiens	74-84
20694294-2	2010	Therefore, the potential ability of Etoricoxib, a selective cycloxygenase-2(COX-2) inhibitor and Diclofenac, a preferential COX-2 inhibitor are considered in the chemoprevention of 1, 2-dimethylhydrazine (DMH) induced colon carcinogenesis in rat model.	Etoricoxib	36-46	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	76-81
20504378-1	2010	BACKGROUND AND OBJECTIVE: Our objective was to report on the design and essentials of the Etoricoxib protocol- Preemptive and Postoperative Analgesia (EPPA) Trial, investigating whether preemptive analgesia with cox-2 inhibitors is more efficacious than placebo in patients who receive either laparotomy or thoracotomy.	Etoricoxib	90-100	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	212-217
20609063-12	2010	CONCLUSIONS: The obtained results suggest that the preferential cyclooxygenase-2 inhibitor etoricoxib significantly reduced the anticonvulsant action of phenytoin and significantly increased the beneficial action of diazepam against maximal electroshock and pentylenetetrazole-induced convulsions in a mouse model.	Etoricoxib	91-101	prostaglandin-endoperoxide synthase 2	Mus musculus	64-80
20399943-11	2010	GA with premedication: The cyclooxygenase (COX)-2 inhibitor etoricoxib; the nonselective COX inhibitors lornoxicam, diclofenac and ketorolac IM; and the opioid nalbuphine improved postoperative pain.	Etoricoxib	60-70	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	27-49
21198287-0	2010	Anti-proliferative and apoptotic effects of etoricoxib, a selective COX-2 inhibitor, on 1,2-dimethylhydrazine dihydrochloride-induced colon carcinogenesis.	Etoricoxib	44-54	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	68-73
20363696-2	2010	Etoricoxib is a new non-steroidal anti-inflammatory drug (NSAID) with selective cox-2 inhibitory activity, selective inhibition of cox-2 provides anti-inflammatory and analgesic activity it is commonly used for osteo-arthritis, rheumatoid arthritis, primary dysmenorrhoea, post operative dental pain and acute gout.	Etoricoxib	0-10	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	80-85
20363696-2	2010	Etoricoxib is a new non-steroidal anti-inflammatory drug (NSAID) with selective cox-2 inhibitory activity, selective inhibition of cox-2 provides anti-inflammatory and analgesic activity it is commonly used for osteo-arthritis, rheumatoid arthritis, primary dysmenorrhoea, post operative dental pain and acute gout.	Etoricoxib	0-10	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	131-136
20052461-8	2010	PGE(2) production in tissue was significantly blocked by the COX-2 inhibitor starting with the appearance of etoricoxib in tissue and lasting for the whole observation period of 24 h (P &lt; 0.01).	Etoricoxib	109-119	prostaglandin-endoperoxide synthase 2	Homo sapiens	61-66
21198287-7	2010	Expression of proliferative cell nuclear antigen (PCNA), assessed by Western blot analysis and immunohistochemistry, was found to be elevated by DMH treatment group and again reduced by etoricoxib.	Etoricoxib	186-196	proliferating cell nuclear antigen	Rattus norvegicus	50-54
20192600-1	2009	Etoricoxib, a highly selective cyclooxygenase- 2 (COX-2) inhibitor (a non steroidal anti-inflammatory drug) used for the treatment of rheumatoid arthritis and osteoarthritis, has been newly marketed and studied for the chemopreventive response in the 1,2-dimethylhydrazine dihydrochloride (DMH) induced rat colon cancer model.	Etoricoxib	0-10	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	31-48
20877132-6	2010	For other cyclooxygenase-2 inhibitors celecoxib, etoricoxib, rofecoxib and valdecoxib, slight to moderate inhibition of hOAT3 only was observed.	Etoricoxib	49-59	prostaglandin-endoperoxide synthase 2	Homo sapiens	10-26
20877132-6	2010	For other cyclooxygenase-2 inhibitors celecoxib, etoricoxib, rofecoxib and valdecoxib, slight to moderate inhibition of hOAT3 only was observed.	Etoricoxib	49-59	solute carrier family 22 member 8	Homo sapiens	120-125
19634927-1	2009	Etoricoxib is a selective cyclo-oxygenase (COX)-2 inhibitor, approved in Europe for the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis.	Etoricoxib	0-10	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	26-49
19338584-10	2009	Furthermore, in HeLa cells after induction of COX2 by tumour necrosis factor alpha and subsequent PGE(2) release, inhibition of COX2 by etoricoxib did not affect HAS expression or HA secretion.	Etoricoxib	136-146	prostaglandin-endoperoxide synthase 2	Homo sapiens	128-132
19721906-1	2009	The present study was designed to investigate the effects of a selective COX-2 inhibitor, etoricoxib in rats on the hematological and toxicity parameters in colon and kidney at two different doses of the drug, one within the therapeutic anti-inflammatory range as based on the reported ED50 value (Eto-1) while the other at ten times higher (Eto-2), relative to the toxicity studies which have not been reported so far.	Etoricoxib	90-100	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	73-78
18952694-6	2009	Under this inflammatory condition, the COX-2 inhibitors DFU (1 micromol/L), DuP-697 (0.5 micromol/L), and Etoricoxib (1 micromol/L) markedly restored and increased the vascular reactivity to NE.	Etoricoxib	106-116	prostaglandin-endoperoxide synthase 2	Homo sapiens	39-44
20204254-0	2010	Effect of etoricoxib, a cyclooxygenase-2 selective inhibitor on aberrant crypt formation and apoptosis in 1,2 dimethyl hydrazine induced colon carcinogenesis in rat model.	Etoricoxib	10-20	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	24-40
20204254-1	2010	Etoricoxib, a second generation selective cyclooxygenase-2 (COX-2) inhibitor had been studied for the chemopreventive response at its therapeutic anti-inflammatory dose in 1,2-dimethylhydrazine (DMH) induced colon carcinogenesis in rat model.	Etoricoxib	0-10	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	42-58
20204254-1	2010	Etoricoxib, a second generation selective cyclooxygenase-2 (COX-2) inhibitor had been studied for the chemopreventive response at its therapeutic anti-inflammatory dose in 1,2-dimethylhydrazine (DMH) induced colon carcinogenesis in rat model.	Etoricoxib	0-10	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	60-65
19589894-0	2009	Early response to COX-2 inhibitors as a predictor of overall response in osteoarthritis: pooled results from two identical trials comparing etoricoxib, celecoxib and placebo.	Etoricoxib	140-150	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	18-23
19470170-13	2009	The cox-2 inhibitor Etoricoxib was found to negate or increase the action of two other drugs (Leflunomide and Dexamethasone).	Etoricoxib	20-30	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	4-9
19516186-6	2009	Etoricoxib (vs. diclofenac) was also significantly associated with increased SBP (P &lt; 0.0001), DPB (P &lt; 0.0001 to P = 0.0015), and exceeding SBP PLoC (P &lt; 0.0001 to P = 0.002).	Etoricoxib	0-10	selenium binding protein 1	Homo sapiens	77-80
19516186-6	2009	Etoricoxib (vs. diclofenac) was also significantly associated with increased SBP (P &lt; 0.0001), DPB (P &lt; 0.0001 to P = 0.0015), and exceeding SBP PLoC (P &lt; 0.0001 to P = 0.002).	Etoricoxib	0-10	selenium binding protein 1	Homo sapiens	147-150
20192600-1	2009	Etoricoxib, a highly selective cyclooxygenase- 2 (COX-2) inhibitor (a non steroidal anti-inflammatory drug) used for the treatment of rheumatoid arthritis and osteoarthritis, has been newly marketed and studied for the chemopreventive response in the 1,2-dimethylhydrazine dihydrochloride (DMH) induced rat colon cancer model.	Etoricoxib	0-10	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	50-55
20192600-13	2009	Studies of a nuclear transcription factor (NF-kB) and COX-2 by Western blot analysis and immunohistochemistry demonstrated expression of both to be elevated in the DMH treated group but reduced in the DMH + Etoricoxib group.	Etoricoxib	207-217	nuclear factor kappa B subunit 1	Rattus norvegicus	43-48
20192600-13	2009	Studies of a nuclear transcription factor (NF-kB) and COX-2 by Western blot analysis and immunohistochemistry demonstrated expression of both to be elevated in the DMH treated group but reduced in the DMH + Etoricoxib group.	Etoricoxib	207-217	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	54-59
18823299-2	2008	The aim was to investigate whether the cyclooxygenase-2 selective nonsteroidal anti-inflammatory drug etoricoxib affects the steady-state pharmacokinetics of digoxin.	Etoricoxib	102-112	prostaglandin-endoperoxide synthase 2	Homo sapiens	39-55
19392653-0	2009	The cyclooxygenase-2 inhibitor etoricoxib is a potent chemopreventive agent of colon carcinogenesis in the rat model.	Etoricoxib	31-41	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	4-20
19392653-1	2009	Cyclooxygenase-2 (COX-2), an inducible prostaglandin G/H synthase, is overexpressed in several human cancers, including colon cancer, and therefore the potential ability of a selective COX-2 inhibitor, etoricoxib, is considered in the prevention of the 1,2-dimethyl hydrazine (DMH)-induced colon carcinogenesis in the rat model.	Etoricoxib	202-212	prostaglandin-endoperoxide synthase 2	Homo sapiens	0-16
19392653-1	2009	Cyclooxygenase-2 (COX-2), an inducible prostaglandin G/H synthase, is overexpressed in several human cancers, including colon cancer, and therefore the potential ability of a selective COX-2 inhibitor, etoricoxib, is considered in the prevention of the 1,2-dimethyl hydrazine (DMH)-induced colon carcinogenesis in the rat model.	Etoricoxib	202-212	prostaglandin-endoperoxide synthase 2	Homo sapiens	18-23
18777173-4	2009	CONCLUSIONS: Miconazole oral gel and oral voriconazole produced comparable increase in the exposure to etoricoxib, presumably via CYP3A inhibition.	Etoricoxib	103-113	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	130-135
19235548-1	2009	Mechanism of interaction of six cox-2 inhibitors--celecoxib, valdecoxib, etoricoxib, parecoxib sodium, meloxicam and nimesulide--with bovine serum albumin (BSA) was studied using fluorescence spectroscopic technique.	Etoricoxib	73-83	albumin	Homo sapiens	141-154
20157362-5	2008	The hypothesis was that etoricoxib would be non-inferior or superior to placebo in effect on C-reactive protein (CRP), LDL-cholesterol, homocysteine, and fibrinogen.	Etoricoxib	24-34	C-reactive protein	Homo sapiens	93-111
23100954-5	2008	We found a short course of Cox-2 (etoricoxib) inhibitor to be an extremely useful adjunct.	Etoricoxib	34-44	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	27-32
19209280-7	2008	We will describe possible strategies to reduce the side effects of etoricoxib by using biochemical markers of COX inhibition, such as whole blood COX-2 and the assessment of prostacyclin biosynthesis in vivo.	Etoricoxib	67-77	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	146-151
19109739-2	2008	Here, we compared etoricoxib, a specific COX-2 inhibitor, with other cyclooxygenase inhibitors on articular incapacitation, edema, leukocyte migration, and gastric damage, in a model of LPS-induced reactive arthritis in rats.	Etoricoxib	18-28	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	41-46
19109739-10	2008	CONCLUSION: The present results suggest that the selective COX-2 inhibitor etoricoxib could be a better option than non-selective COX inhibitors, since it presented a potent inhibitory effect on the clinical signals and also a potent inhibition on cell migration.	Etoricoxib	75-85	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	59-64
18823986-0	2008	Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac.	Etoricoxib	99-109	prostaglandin-endoperoxide synthase 2	Homo sapiens	61-78
20157362-5	2008	The hypothesis was that etoricoxib would be non-inferior or superior to placebo in effect on C-reactive protein (CRP), LDL-cholesterol, homocysteine, and fibrinogen.	Etoricoxib	24-34	C-reactive protein	Homo sapiens	113-116
20157362-5	2008	The hypothesis was that etoricoxib would be non-inferior or superior to placebo in effect on C-reactive protein (CRP), LDL-cholesterol, homocysteine, and fibrinogen.	Etoricoxib	24-34	fibrinogen beta chain	Homo sapiens	154-164
18661871-1	2008	Etoricoxib is a cyclooxygenase 2 (COX-2) inhibitor that selectively inhibits the COX-2 enzyme and decreases the incidences of side effects associated with these agents.	Etoricoxib	0-10	prostaglandin-endoperoxide synthase 2	Homo sapiens	16-32
18434566-0	2008	Comparative inhibitory activity of etoricoxib, celecoxib, and diclofenac on COX-2 versus COX-1 in healthy subjects.	Etoricoxib	35-45	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	76-81
18661871-1	2008	Etoricoxib is a cyclooxygenase 2 (COX-2) inhibitor that selectively inhibits the COX-2 enzyme and decreases the incidences of side effects associated with these agents.	Etoricoxib	0-10	prostaglandin-endoperoxide synthase 2	Homo sapiens	34-39
18661871-1	2008	Etoricoxib is a cyclooxygenase 2 (COX-2) inhibitor that selectively inhibits the COX-2 enzyme and decreases the incidences of side effects associated with these agents.	Etoricoxib	0-10	prostaglandin-endoperoxide synthase 2	Homo sapiens	81-86
17999057-8	2008	All are eliminated by hepatic metabolism involving mainly CYP2C9 (celecoxib, lumiracoxib) and CYP3A4 (etoricoxib).	Etoricoxib	102-112	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	94-100
18405470-0	2008	Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.	Etoricoxib	109-119	prostaglandin-endoperoxide synthase 2	Homo sapiens	0-16
18405470-1	2008	OBJECTIVES: To review the clinical effectiveness and cost-effectiveness of cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drugs (NSAIDs) (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis (OA) and rheumatoid arthritis (RA).	Etoricoxib	201-211	prostaglandin-endoperoxide synthase 2	Homo sapiens	75-91
18405470-1	2008	OBJECTIVES: To review the clinical effectiveness and cost-effectiveness of cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drugs (NSAIDs) (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis (OA) and rheumatoid arthritis (RA).	Etoricoxib	201-211	prostaglandin-endoperoxide synthase 2	Homo sapiens	93-98
18443385-1	2008	Etoricoxib is presently the most commonly prescribed cyclooxygenase-2 (Cox-2) inhibitor for chronic pain and inflammatory conditions.	Etoricoxib	0-10	prostaglandin-endoperoxide synthase 2	Homo sapiens	53-69
18443385-1	2008	Etoricoxib is presently the most commonly prescribed cyclooxygenase-2 (Cox-2) inhibitor for chronic pain and inflammatory conditions.	Etoricoxib	0-10	prostaglandin-endoperoxide synthase 2	Homo sapiens	71-76
18443385-3	2008	Hence, there are chances of drug-drug interaction because modulations of isoenzymes involved in metabolism CYP2C9/10 and CYP2C19 which partially inhibited by etoricoxib.	Etoricoxib	158-168	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	107-113
18443385-3	2008	Hence, there are chances of drug-drug interaction because modulations of isoenzymes involved in metabolism CYP2C9/10 and CYP2C19 which partially inhibited by etoricoxib.	Etoricoxib	158-168	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	121-128
18182814-1	2008	Etoricoxib is a new, highly selective cyclooxygenase (COX) 2 inhibitor, reported to have an increased cutaneous and systemic safety profile compared to the previous COX-2 inhibitors, including celecoxib, rofecoxib and valdecoxib.	Etoricoxib	0-10	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	38-60
17931847-5	2008	Modulating effects of dexamethasone, ibuprofen, MK-663 or triptolide on ICAM-1 regulation were investigated in vitro.	Etoricoxib	48-54	intercellular adhesion molecule 1	Homo sapiens	72-78
18182814-1	2008	Etoricoxib is a new, highly selective cyclooxygenase (COX) 2 inhibitor, reported to have an increased cutaneous and systemic safety profile compared to the previous COX-2 inhibitors, including celecoxib, rofecoxib and valdecoxib.	Etoricoxib	0-10	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	165-170
18564626-3	2008	Here we report the safety and tolerability of etoricoxib, a selective COX-2 inhibitor with fewer cardiovascular effects, in patients with adverse reactions to NSAIDs.	Etoricoxib	46-56	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	70-75
18171381-0	2008	Primary stabbing headache can be responsive to etoricoxib, a selective COX-2 inhibitor.	Etoricoxib	47-57	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	71-76
17638016-8	2008	Treatment 1 h before IFS injection with etoricoxib, indomethacin, thalidomide, and pentoxifylline reduced COX-2 expression and some macroscopic and microscopic parameters in IFS-induced HC.	Etoricoxib	40-50	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	106-111
17953635-4	2007	This study aimed to detect tolerability of etoricoxib, a selective COX-2-inhibiting drug, in patients with chronic urticaria with a history of NSAID intolerance.	Etoricoxib	43-53	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	67-72
19105535-0	2008	Cyclooxygenase-2 inhibition by etoricoxib modulates plasma membrane fluidity in rat colon.	Etoricoxib	31-41	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	0-16
19105535-1	2008	The present study was designed to investigate the effects of a selective cycloogenase-2 (COX-2) inhibitor, etoricoxib, on the membrane-specific enzymes, lipid composition, and changes in fluidity parameters of rat colonic plasma membrane.	Etoricoxib	107-117	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	89-94
19105535-8	2008	It is concluded that etoricoxib, a new generation COX-2 inhibitor (called the coxibs), appeared to be a safe nonsteroidal anti-inflammatory drug (NSAID) in the colonic membranes.	Etoricoxib	21-31	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	50-55
18516314-2	2007	One particular NSAID, which is a highly selective cyclo-oxygenase 2 inhibitor, etoricoxib, may be superior to standard NSAIDs for AS.	Etoricoxib	79-89	prostaglandin-endoperoxide synthase 2	Homo sapiens	50-67
17953635-7	2007	The study suggests that etoricoxib, with its favourable COX-1/COX-2 ratio, is well tolerated by patients with chronic urticaria exacerbated by NSAID intolerance.	Etoricoxib	24-34	prostaglandin-endoperoxide synthase 1	Homo sapiens	56-61
17953635-7	2007	The study suggests that etoricoxib, with its favourable COX-1/COX-2 ratio, is well tolerated by patients with chronic urticaria exacerbated by NSAID intolerance.	Etoricoxib	24-34	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	62-67
17697449-1	2007	BACKGROUND: Etoricoxib is a cyclooxygenase-2 (COX-2) selective inhibitor effective in the treatment of rheumatoid arthritis.	Etoricoxib	12-22	prostaglandin-endoperoxide synthase 2	Homo sapiens	28-44
17697449-1	2007	BACKGROUND: Etoricoxib is a cyclooxygenase-2 (COX-2) selective inhibitor effective in the treatment of rheumatoid arthritis.	Etoricoxib	12-22	prostaglandin-endoperoxide synthase 2	Homo sapiens	46-51
17452571-6	2007	Etoricoxib improved the sleep parameters, suggesting the involvement of the cyclo-oxygenase-2 enzyme in acute inflammation of the TMJ, specifically in REM sleep.	Etoricoxib	0-10	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	76-93
17701021-1	2007	This study has evaluated the anti-inflammatory and analgesic responses of etoricoxib, a selective COX-2 non-steroidal anti-inflammatory drug combined with misoprostol in pre-clinical assays.	Etoricoxib	74-84	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	98-103
17915794-1	2007	Diclofenac sodium, a non-selective cyclo-oxygenase inhibitor and etoricoxib, a selective cyclo-oxygenase-2 inhibitor have been widely used in treatment of patients with osteo-arthritis.	Etoricoxib	65-75	prostaglandin-endoperoxide synthase 2	Homo sapiens	89-106
17915794-4	2007	The study shows that etoricoxib provides better clinical efficacy and gastro-intestinal tolerability in osteo-arthritis in comparison to diclofenac sodium presumably due to the selective inhibition of cyclo-oxygenase-2 by etoricoxib.	Etoricoxib	21-31	prostaglandin-endoperoxide synthase 2	Homo sapiens	201-218
17915794-4	2007	The study shows that etoricoxib provides better clinical efficacy and gastro-intestinal tolerability in osteo-arthritis in comparison to diclofenac sodium presumably due to the selective inhibition of cyclo-oxygenase-2 by etoricoxib.	Etoricoxib	222-232	prostaglandin-endoperoxide synthase 2	Homo sapiens	201-218
17292766-9	2007	INTERPRETATION: There were significantly fewer upper gastrointestinal clinical events with the COX-2 selective inhibitor etoricoxib than with the traditional NSAID diclofenac due to a decrease in uncomplicated events, but not in the more serious complicated events.	Etoricoxib	121-131	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	95-100
17155937-2	2007	Etoricoxib is a new cyclo-oxygenase-2 inhibitor with a long duration of action and a lack of a deteriorating effect on platelet function.	Etoricoxib	0-10	prostaglandin-endoperoxide synthase 2	Homo sapiens	20-37
17278926-8	2007	For treatment of gouty inflammation, etoricoxib (a new cyclooxygenase 2 inhibitor) has been shown to be as effective as indomethacin.	Etoricoxib	37-47	prostaglandin-endoperoxide synthase 2	Homo sapiens	55-71
17304885-2	2007	OBJECTIVE: To evaluate tolerance to etoricoxib, a new cyclooxygenase-2 inhibitor, in NSAID-sensitive patients with urticaria-type adverse reactions.	Etoricoxib	36-46	prostaglandin-endoperoxide synthase 2	Homo sapiens	54-70
17304885-6	2007	CONCLUSIONS: Etoricoxib, like other cyclooxygenase-2 inhibitors, is a well-tolerated drug in most NSAID-sensitive patients.	Etoricoxib	13-23	prostaglandin-endoperoxide synthase 2	Homo sapiens	36-52
17691996-7	2007	This review examines the role of the newest COX-2 selective inhibitors, etoricoxib and lumiracoxib, in treating rheumatic disease.	Etoricoxib	72-82	prostaglandin-endoperoxide synthase 2	Homo sapiens	44-49
17691997-2	2007	Etoricoxib and lumiracoxib are regarded as second generation coxibs because of their higher COX-2 selectivity.	Etoricoxib	0-10	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	92-97
17228166-3	2007	Our aim was to investigate the clinical tolerability of etoricoxib, a new selective cyclooxygenase-2 inhibitor, in a group of patients with well-established NSAID hypersensitivity.	Etoricoxib	56-66	prostaglandin-endoperoxide synthase 2	Homo sapiens	84-100